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ABSTRACT - Years after the first report on 1,4-dihydropyridines (1,4-DHPs) and 1,2,3,4-
tetrahydropyrimidines (1,2,3,4-THPMs) appeared, they  are revisited as plausible therapeutic agents. This is 
mainly due to the convenient methods that exist for their synthesis and the diverse pharmacologic properties that 
these scaffolds present. 1,4-Dihydropyridines and 1,2,3,4-tetrahydropyrimidines are usually regarded as 
analogous in several aspects. They are both prepared in multi-component reactions using very similar starting 
materials and synthesis protocols. This leads to common structural features between 1,4-DHPs and 1,2,3,4-
THPMs, as well several related biological effects. For example, they share many pharmacological features such 
as analgesic, anti-tumor, antioxidant, anti-inflammatory, antitubercular, antibacterial, cardiovascular and 
adrenoceptor blocking activities. Numerous reviews have been devoted to the chemistry and cardiovascular 
effects of these compounds.  However, the lack of a comprehensive literature overview on the chemotherapeutic 
ability of these scaffolds  is behind the present attempt to provide a detailed survey of 1,4-DHPs and 1,2,3,4-
THPMs and their structural features as chemotherapeutic agents. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
__________________________________________________________________________________________ 
 
INTRODUCTION 
In the last two decades of the nineteenth century 
two analogous chemical scaffolds were introduced 
to organic chemistry, which were later to have a 
great impact on pharmacology and medicinal 
chemistry. Arthur Hantzsch in 1882, and Pietro 
Biginelli in 1893, reported methods for the 
synthesis of 1,4-dihydropyridine (1,4-DHP) and 
1,2,3,4-tetrahydropyrimidine (1,2,3,4-THPM) 
structures, respectively, which now bear their 
names (1,2). They were similar scaffolds in several 
aspects, each being prepared in a multi-component 
reaction (MCR), a very useful method in organic 
synthesis, which was still in its early years. 
Acetoacetate esters and aromatic aldehydes were 
the two components common in both reactions. 
This led to common structural features between 1,4-
DHPs and 1,2,3,4-THPMs, the latter of which could 
be regarded as the aza analogue of the former from 
a structural point of view. After years of being 
neglected, both these chemical scaffolds attracted 
considerable attention by medicinal chemists in the 
last three decades of the twentieth century. This was 
due to their diverse pharmacologic properties, 
which included analgesic (3,4) anti-tumor (5-7), 
antioxidant (8,9), anti-inflammatory (10,11), 
antitubercular (12,13), cardiovascular (14,15), 
adrenoceptor blocking (16), and antibacterial 
(17,18) activities. Nonetheless, 1,4-
dihydropyridines are mostly known for their 
cardiovascular effects because, since their 
introduction into clinical practice in 1975, they have 
primarily been  used as calcium channel modulators 
(19). 1,2,3,4-Tetrahydropyrimidines have also been 
evaluated as calcium channel modulating agents 
due to their structural similarity to 1,4-
dihydropyridines (20), and several reviews have 
been devoted to the chemistry and synthesis of 
these two chemical scaffolds (21-35). The calcium 
channel modulating activity of both scaffolds has 
also led to numerous reviews dedicated to 
biological responses initiated by this property (36-  
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51). However, little is about other biological 
capacities of 1,4-DHPs and 1,2,3,4-THPMs     (52-
57). 
In this review, we provide a literature overview 
on the chemotherapeutic ability of these two 
scaffolds. A detailed survey of the antitubercular, 
antibacterial, antifungal and cytotoxic activities 
described for 1,4-dihydropyridine and 1,2,3,4-
tetrahydropyrimidine analogues, from 2001 to the 
present is made. Since the general methods for the 
synthesis of these scaffolds, known as the Biginelli 
and Hantzsch reactions, and different strategies for 
the preparation of the more complicated derivatives 
have been discussed in several reviews, nothing is 
provided here about this subject and only their 
pharmacological properties are discussed.  
  
1,4-DIHYDROPYRIDINES 
ANTITUBERCULAR ACTIVITY  
Somebody somewhere in the world is newly 
infected with tuberculosis (TB) bacilli every second 
and one-third of the world’s population currently 
suffers from this disease. An estimated 1.5 million 
people die from TB each year (58). 
Tuberculosis is principally caused by 
Mycobacterium tuberculosis, a remarkably 
successful airborne pathogen (59). The infection 
spreads through the air, but is both preventable and 
curable. The major solution to the problem is 
chemotherapy, which requires the development of 
effective and non-toxic antitubercular agents. The 
emergence of multi-drug resistance (MDR) has 
forced the development of new structural classes of 
antitubercular agents, several of which have shown 
promising activity. In this respect, 1,4-
dihydropyridines and 1,2,3,4-tetrahydropyrimidines 
are excellent starting scaffolds for the development 
of antiTB agents against the best-characterized 
strain of Mycobacterium tuberculosis, H37Rv (60-
62).  
The first report of 1,4-dihydropyridine as an 
antitubercular scaffold  dates back to 2001, when 
Desai et al. described the high antitubercular 
activity for of 1,4-dihydropyridine 3,5-
dicarboxamide and 3,5-dicarboxylate ester 
derivatives (63). Since that time, it has been 
demonstrated that some features of dihydropyridine 
substituents have important effects on the antiTB 
activity of these compounds. The most studied 
features are the type of C-3, C-4 and C-5 
substituents and also the lipophilicity of the 
compound. Most of the reported antitubercular 1,4-
DHPs fall into one of the three structural categories 
shown in Figure 1. 
The first antitubercular 1,4-DHPs introduced 
were 3,5-dicarboxamide derivatives rather than 3,5-
dicarboxylate esters, which had been known as 
antihypertensive agents for decades (63). Other 
researchers identified more antitubercular 
derivatives of this scaffold (12,64,65). Asymmetric 
1,4-DHPs bearing one carboxylate ester group and 
symmetric analogues with carboxylate ester groups 
in both C-3 and C-5 positions were also reported as 
potent antitubercular agents (62,66-68), C-3 and C-
5 derivatives in most cases  being a (substituted) 
phenylcarboxamide moiety. There are also some 
reports of using heteroaromatic carboxamides in 
these positions (12,69). In C-4 position, substituted 
phenyl (61,63,66,69) and several heteroaromatic 
rings (12,62,64,67,68,70) have been studied. N-1 
(substituted) phenyl substitutions exist in the 
structure of some of the antitubercular 1,4-DHPs 
(61,62,68). 
Lipophilicity seems to be an important property 
since the microorganism cell wall is lipophilic in 
character and C-3, C-4 and C-5 substituents provide 
the necessary lipophilicity to the compounds. These 
positions are always substituted by lipophilic 
aromatic moieties. It is believed that phenyl 
substituted 3,5-dicarboxamides are in fact lipophilic 
prodrugs of the active dicarboxylic derivatives 
which cannot easily pass through the cell wall (63). 
The 3,5-dicarboxamide groups undergo hydrolysis 
to the parent dicarboxylic acid derivatives at the site 
of action (12,61-70).  
 
NH
NHArArHN
Ar
H3C CH3
OO
NH
ORRO
Ar
H3C CH3
OO
NH
NHAr(R)RO
Ar
H3C CH3
OO
 Figure 1. Structural categories of antitubercular 1,4-DHPs 
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Kharkar et al. (70) concluded that ortho substitution 
on the C-3 and C-5 phenyl moieties sterically 
reduce the rate of amide bond hydrolysis, 
decreasing the antitubercular activity of the 
compound. Examples of this are 1a and 1b, the 
former compound being substantially more active 
than the latter (12) Figure 2. 
 
NHH3C CH3
NH NH
R R
N
N
S
H3C
OO
X
       X            R               MICa (g/mL)
1a  CH2     p-ClC6H5            1
1b  CH2     o-ClC6H5        >16
Rifampicin                           1     
Isoniazide                             0.2
a MIC= Minimum Inhibitory Concentration   
Figure 2. Chemical structures and antitubercular 
activities of 1a and 1b 
 
Other examples can be found in the report provided 
by Manvar et al. (61). Compound 2a with ortho-Cl 
is less active than 2b with meta-Cl (Figure 3).  
 
NHH3C CH3
NH NH
R1 R2OO
            R1 , R2        R3      
2a         o-Cl          o-Cl    (PIa  at >12.5g/mL = 11)
2b        m-Cl          o-Cl    (PI  at > 6.25g/mL = 72)
Rifampicin                      (PI  at > 6.25g/mL = 97)
a PI= Percentage of Inhibition
R3
 
Figure 3. Chemical structures and PIs (%) of 2a and 2b  
Kharkar et al. (70) also concluded that electron-
withdrawing groups in meta and para positions of 
the C-3 and C-5 phenyl carboxamide moieties 
increase the antiTB potency. This is not exemplified 
well in their report but a good example can be seen 
in other reports. 3a (PI at 2.5 µg/mL = 98) and 3b 
(PI at 2.5µg/mL = 97) are meta/para nitro phenyl 
compounds with high antitubercular activity as 
indicated in (70) Figure 4. 
NHH3C CH3
NH NH
R1 R1OO
            R1            R
3a    m-NO2      p-SCH3    
3b     p-NO2      p-SCH3
R
 
Figure 4. Chemical structures of 3a and 3b 
 
It is interesting that 2c with para-Cl is also very 
weak compared with 2b with its meta-Cl 
substitution (61) Figure 5. The reason is that the 
chloro group in para position is an electron-
releasing rather electron-withdrawing group, while 
the chloro group in meta position is electron-
withdrawing.  
NHH3C CH3
CONHHNOCCl Cl
Cl
2c                  (PI  at >12.5mg/mL = 6)
Rifampicin   (PI  at > 6.25mg/mL = 97)  
Figure 5. Structure and antitubercular activity of 
compound 2c 
 
 
Asymmetric 3,5-dicarboxamide 1,4-dihydro-
pyridines with two different dicarboxamide 
derivatives have also been evaluated as antiTB 
agents but, compared to the symmetric equivalents, 
they show weaker activity (61). Asymmetric 1,4-
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DHPs bearing a carboxylate ester and a 
dicarboxamide group  have also been studied for 
antitubercular activity as mentioned above. 
Khoshneviszadeh et al. (67) introduced into alkyl 
(4a-e) or aralkyl (4f-j) esters to 1,4-
dihydropyridines substituted with one carboxamide 
group at the C-5 position (Figure 6). 
Aralkyl esters were found to be more potent, 
with a potency that depended on the number of 
methylen groups they contained in the aralkyl ester 
group. Benzyl, phenethyl and phenpropyl esters 
were most potent and further increases in the length 
of the chain led to a fifty percent reduction of the 
activity (67). This can be explained by the effect of 
the optimum lipophilicity on the potency (discussed 
below). Although alkyl esters were weaker 
antitubercular agents, they showed the same 
relationship between potency and lipophilicity.   
Optimum lipophilicity is probably necessary for 
the compound to become an active antiTB agent, as 
was suggested by Kharkar et al. (70), who 
developed 3D-quantitative structure–activity 
relationship (3D-QSAR) models, and observed that 
the parameter CLogP had no effect on the 
significance of the CoMFA and CoMSIA models 
obtained. Compound 3c (PI at 2.5 µg/mL = 98) was 
less lipophilic than 3d (PI at 2.5 µg/mL = 11) 
Figure 7, confirming that the third chloro group in 
the latter compound does not have a positive effect 
on the antiTB activity (6,14). Compound 3e, which 
was even less lipophilic than 3c, showed high 
antitubercular activity (PI at 2.5 µg/mL = 94). 
In the same vein, compound 4j (MIC = 2 
μg/mL), with its higher LogP (2.23 vs 0.79) than 
compound 4f (MIC = 1 μg/mL) had half of its 
antitubercular activity (68) Figure 6. Thus, besides 
this physicochemical property, other structural 
features also determine the potency; for example, 
the effect of the polar electron-withdrawing nitro 
groups substituted on the C-3 and C-5 phenyl 
carboxamide moieties discussed above (61,70).  
Analysis of the structure of the antiTB 1,4-
DHPs reported by Fassihi et al. (12) revealed that 
replacing the NH moiety with CH2 in the less 
lipophilic compound 1c increased its potency. 
Meta-Cl isomer 1d was much weaker, than the 
active para-isomer 1a. This is in contrast with the 
explanation of the differences between 2b and 2c 
activities (60) Figures 2,8, mentioned previously, 
which suggests that other factors are determinants 
of the potencies. 
 
 
NHH3C CH3
OR NH C2H5
C2H5OO
NN
O2N
H3C
            R                        MIC (g/mL)
4a    CH3                            >500 4b    CH2CH3                       250 4c    CH(CH3)2                   >500 4d    (CH2)2CH3                       2 4e    (CH2)3CH3                        1
NHH3C CH3
OAr NH C2H5
C2H5OO
NN
O2N
H3C
              Ar                       MIC (g/mL)
4f    CH2-C6H5                       1 4g   (CH2)2C6H5                     14h   (CH2)3C6H5                     1 4i    (CH2)4C6H5                     2 4j    (CH2)5C6H5                     2Isoniazide                               1
Rifampicin                             1  
 
Figure 6. Chemical structures and MICs (µg/mL) of asymmetric 1,4-dihydropyridines  
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NHH3C CH3
NH NH
R1 R1OO
           R1                 R
3c     m-NO2       o,p-(Cl)2  
3d     o-Cl           o,p-(Cl)2
3e     m-NO2            H
R
  
Figure 7. Structures of 3c-e 
 
 
   
 
NHH3C CH3
NH NH
R R
N
N
S
H3C
OO
X
         X              R              MIC ( g/mL) 
1c    NH       p-ClC6H5         >16 1d    CH2     m-ClC6H5          >16Rifampicin                              1
Isoniazide                                0.2   
Figure 8. Chemical structures and MICs of 1c and 1d 
 
 
The presence of different aromatic moieties at 
the C-4 position of the dihydropyridine ring has 
been seen to affect the antiTB activity, partly by 
providing the desired lipophilicity to the molecule 
(62,64,65,67,68,70). Phenyl substituted groups were 
the first aromatic moieties evaluated in this position 
(61,63,66). Compound 3f (LogP = -0.3888) was 
reported to be less reactive than 3g with a LogP of 
1.1949, confirming the effect of the lipophilicity on 
the potency (63,70) Figure 9. 
 
 
 
 
NHH3C CH3
NH NH
R1 R1OO
            R1           R                       PI at 2.5g/mL
3f       p-Cl      m-NO2                         29
3g      p-Cl      m,p,m'-(OCH3)3           94
Rifampicin                                         95
R
  
Figure 9. Structure and antitubercular activity (PI) of 3f 
and 3g 
 
 
Here again some controversy exists between the 
different reports, confirming the involvement of 
other factors as stated previously. For example, 2d 
with one more nitro group in its structure was more 
potent than 2e and even more potent than 2f and 2g 
(PIs at > 6.25 µg/mL = 64, 42, 29 and 28, 
respectively), which contain halogen atoms in their 
structures (61) Figure 10.  
 
NHH3C CH3
NH NH
R1 R2OO
R3
          R1, R2              R3
2d      m-NO2          o-NO2   
2e      m-NO2              H
2f        p-F               o-NO2
2g       p-F               o-Cl   
Figure 10. Chemical structures of 2d-g 
 
 
Presumably some kinds of electrostatic 
interactions or hydrogen bonding is involved in the 
attachment of the molecule to its site of action. 
According to a 3D-QSAR study published by 
Kharkar et al. (70), the presence of para 
substituents with rotatable bonds at the C-4 
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position, such as -N(CH3)2, -OCH3 and -SCH3, 
increases antiTB activity. The authors assumed the 
involvement of proper hydrogen bonding between 
these substituents and the receptor due to the free 
rotation of these substituents (70). This finding was 
confirmed by Manvar et al. (61) in a more recent 
3D-QSAR study. Some disagreement concerning 
this relationship can be observed in the 
experimental data, again suggesting that other 
factors are determining the potency of the 
compounds. For example, 2h and 2i (PIs at > 12.5 
µg/mL = 93 and 84, respectively) were strong 
compounds but, 2j (PI at > 12.5 µg/mL = 23) was 
weak, although all had a para-dimethylamino 
phenyl group at the C-4 position with slight 
differences in other substituents (61). In the case of 
the methoxy group in this position, most of the 
compounds were weak: 2k (PI at > 12.5 µg/mL = 
30) was weak and 2l (PI at > 6.25 µg/mL = 71) has 
been shown to be a moderate antitubercular agent 
(Figure 11). Several weak examples can be 
extracted from the data provided by Manvar et al. 
(61).The lack of the data for defining the resonance 
or inductive effects of the substituents on the C-3 
and C-5 phenyl moieties makes it difficult to 
establish a relationship between the effect of the 
above-mentioned C-4 substitutions and the 
antitubercular activity. The assumption made by 
Kharkar et al. (70) that the ortho substitution on the 
C-3 and C-5 phenyl moieties sterically reduces the 
rate of amide bond hydrolysis could be an 
explanation for the weak antitubercular activities of 
some of these compounds. 
NHH3C CH3
NH NH
R1 R2OO
R3
            R1, R2               R3
2h      o-OCH3         p-N(CH3)2   
2i       o-CH3            p-N(CH3)2
2j       o-Cl               p-N(CH3)2
2k      o-Cl               p-OCH3      
2l       m-Cl              p-OCH3   
Figure 11. Structures of 2h-l 
N-1 substitution of the 1,4-dihydropyridine 3,5-
dicarboxylate esters with (substituted) phenyl 
moiety 5a and 5b resulted in compounds with lower 
antiTB activity than unsubstituted compounds (61) 
Figure 12.  
NH3C CH3
OH3C O CH3
OO
R1
                R1                  R2             PI at > 6.25 µg/mL    
5a         m-OC6H5          H                           33 
5b         p-Cl              p-OCH3                      5
Rifampicin                                                 97
R2
 
Figure 12. PIs of antitubercular N-1 substituted 1,4-
dihydropyridine 3,5-dicarboxylate esters  
 
 
However, this cannot be regarded as a rule: for 
example, N-1 substitution (5) did not change the 
potency. This can be concluded by comparing the 
potencies of 6 and 7 (68) Figure 13.  
In an attempt to suggest a putative mechanism 
of action for this class of antitubercular agents 
Mahnam et al. (71) focused on the structural 
similarities of the 1,4-dihydropyridine scaffold to 
NADH, the coenzyme for a key regulatory enzyme 
in fatty acid elongation, trans-2-enoyl-ACP 
reductase. The authors determined the high binding 
affinity of a series of 1,4-dihydropyridine-3,5-
dicarboxamide derivatives to enoyl reductase from 
Mycobacterium tuberculosis using docking and 
molecular dynamics simulation methods. Using the 
same methods, they also obtained high binding 
affinity for the 3,5-dicarboxylic acid derivatives and 
concluded that aryl or heteroaryl substituents at C-3 
and C-5 are not necessary for receptor binding and 
only provide the necessary lipophilicity to the 
molecule. This agrees with the observations of 
Desai et al. and Kharkar et al. that carboxamide 
groups are hydrolyzed to 1,4-dihydropyridine-3,5- 
carboxylic acid derivatives with antibuercular 
activity (12, 61-71). 
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NHH3C CH3
O O
OO
NN
H3C CH3
                       MIC (g/mL)       PI at 1.56 g/mL
 6                         1.56                             95
 7                         1.56                             96
Isoniazide           0.03                               -
NH3C CH3
O O
OO
NN
H3C CH3
6
7
  
Figure 13. Comparison of the antitubercular activity of N-1 substituted and N-1 unsubstituted 1,4-dihydropyridines 
  
ANTIMICROBIAL ACTIVITY  
 
Despite the recent advances in medicine, 
antimicrobial chemotherapy still remains a problem 
in most developing and even developed countries. 
The narrow spectrum of activity of some 
antimicrobial drugs on the market and the many 
serious adverse effects reported explain the reasons 
for the failure of antimicrobial chemotherapy and 
why there is a search for more acceptable 
compounds. The inevitable emergence of resistant 
strains of pathological microorganisms and of the 
growing list of multi-drug resistant strains is 
another serious problem in clinical practice (72).  
Among the many different chemical scaffolds 
screened, 1,4-dihydropyridine compounds have 
attracted attention both as antimicrobial agents and 
MDR-reversing entities because of their ability to 
exert synergistic antibacterial effects in 
combination with known antibiotics (73-99). It has 
been demonstrated that the type of C-3, C-4 and C-
5 substituent and the lipophilicity of the molecule 
have important effects on the antimicrobial activity 
of 1,4-dihydropyridine compounds. Three structural 
categories are found among the antimicrobial 1,4-
DHPs as shown in Figure 14. 
1,4-DHP derivatives containing diethyl 
carbamoyl and ester substituents at C-3 and C-5, 
and substituted aromatic or heteroaromatic ring at 
C-4 position have also been reported as potential 
antimicrobial agents (73-76). An N-1 (substituted) 
phenyl substitution exists in the structure of some of 
the antimicrobial 1,4-DHPs (96-99). 
Maya et al. (75) concluded that the presence of 
a fused ring attached to the dihydropyridine ring 
through the C2=C3 bond of the dihydropyridine 
moiety decreases the antimicrobial activity of the 
compound. Examples of this type of 
dihydropyridine derivatives are 8a, 8b and 8c 
(Figure 15).  
 
NH
NHArArHN
Ar
H3C CH3
OO
NH
ORRO
Ar
H3C CH3
OO
NH
NHNHArArHNHN
Ar
H3C CH3
OO
  
Figure 14. Three structural classes of antimicrobial 1,4-DHPs 
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NH
O
H3C
OH3C
O O
Cl
CH3
CH3
NHH3C
OH3C
O O
Cl
NHH3C
OH3C
O O
Cl
CH3
CH3
8a 8b 8c
                 PI at 10 M 
                   T. cruzi
8a                   10
8b           No Inhibition
8c                    40
Nicardipine    40
Felodipine      32   
Figure 15. Chemical structures and antimicrobial activities of 8a-c 
 
 
In addition, Ladani et al. (76) reported 
antimicrobial dihydropyridin derivatives as 
possessing two cyclic ketones fused to the main 
scaffold, instead of the C-3 and C-5 carboxylate 
derivatives. Compound 9a is an example with good 
fungicidal and poor bactericidal activity, while 
compound 10 (17) displayed good bactericidal 
properties (Figure 16).  
 
NH
O
9a
O
N
N
NN
NH
O
10
O
OH
O CH3
  
Figure 16. Antimicrobial dihydropyridines with cyclic 
ketones fused to the main scaffold 
 
 
Other examples were reported by Dabholkar et 
al. (77). Compounds 11a and 11b showed almost 
equal potency against Escherichia coli and very 
similar activities against Corynebacterium 
diphtheria (gram positive bacteria), Pseudomonas 
aeruginosa and Staphylococcus aureus (gram 
negative bacteria) to the reference drug, Ampicillin 
trihydrate (Figure 17). 
 
NH
R
O O
                                         Zone of inhibition at 100 g/mL (mm)
             R            S. aureus    C. diphtheria      P. aeruginosa       E. coli
11a       Cl               22                    20                      21                       19
11b     OCH3           21                    18                      20                       18Ampicillin               26                    28                      24                        21
 
Figure 17. Chemical structures and zone of inhibition 
values (ZIs) of 11a and 11b 
 
 
Ladani et al (76) and Gunduz et al. (78) 
prepared dihydropyridines with a fused cyclic 
ketone and a carboxylate or carboxamide moiety at 
the C-3 and C-5 positions of the DHP ring, finding 
the compounds to be antimicrobial agents (9b, 12a 
and 12b) (Figure 18). 
Akbarzadeh et al. (79) in 2008 prepared 
antimicrobial 1,4-DHP 3,5-dicarboxamides, which 
were found to be inactive when used as 
antimicrobials alone, but active when used in 
conjunction with Amoxicillin. Comparison of the 
activities of the synthesized symmetrical amides 
indicated that the presence of withdrawing groups, 
especially at the para position of the phenyl 
carboxamide moieties, was essential enhancing 
activity; however, substitution at the meta or ortho 
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positions reduced or eliminated this enhancing 
effect. 13a had no inhibitory activity against S. 
aureus, unlike 13b (79) Figure 19.  
NH
O
O
9b
O
N
N
NN
CH3
CH3
NH
O
O
12a
O
CH3
CH3
H3C
H3C
F
F
NH
N
O
12b
O
CH3
F
F
H3C
CH3
CH3
CH3
 Figure 18. 1,4-DHPs with a fused cyclic ketone and a carboxylate or carboxamide moiety at the C-3 and C-5 positions 
 
NHH3C
NH
O
13b
NH
O ClCl
N
NH3C
PhH2CO2S
NHH3C
NH
O
13a
NH
O
N
NH3C
PhH2CO2S
Cl Cl CH3CH3
                               Zone of inhibitionat 25g/mL (mm)
                                                    S. aureus 
13a+Amoxicillin                     No Inhibition
13b+Amoxicillin                           14   
Figure 19. Chemical structures and antimicrobial activity of 13a and 13b in combination with Amoxicillin 
 
 
The same research group in 2010 reported that 
disubstitution at meta and para positions of the 
phenylcarboxamide moieties with chlorine atoms 
also increased the activity, while the presence of an 
ortho-Cl substitution decreased the potency. This 
conclusion can be exemplified by compounds 14a 
and 14b in combination with Cloxacillin, whose 
joint antibacterial activities were studied against 
Methicillin-resistant S. aureus (MRSA) (80) Figure 
20.  
Sirisha et al. also demonstrated that 1,4-DHP-
3,5-dicarboxamides were more active than 1,4-
DHP-3,5-dicarboxylate esters. Most of the 
compounds they prepared were relatively more 
active against gram negative bacteria. Compound 
15a was almost equipotent to Streptomycin/ 
Tetracyclin against gram negative bacteria [zone of 
inhibition (ZI) = 23, 26 and 25, 21 millimeters in 50 
µg/mL for Escherichia coli and Proteus vulgaris, 
respectively] (Figure 20). But, among the 
compounds they prepared, 15b was more potent 
against a gram positive bacterium, Bacillus subtilis, 
unlike other compounds. The ZI for this compound 
was 18 mm against B. subtilis (Tetracycline: 20 
mm) and 12 against S. aureus (Tetracycline: 22 
mm) both in 50 µg/mL (69) Figure 21.  
Sirisha et al. reported on some more 
antibacterial 1,4-DHPs with higher activities against 
gram negative bacteria in 2011. For example, 16a 
and 16b had significant inhibitory activity against 
E. coli and P. vulgaris. 16a was also found to 
exhibit considerable activity against MRSA (81) 
Figure 22. Compounds with aromatic or 
heteroaromatic rings at C-3 and C-5 
arylcarboxamide moieties were active against the 
pathogenic microorganisms studied (69,81). 
The presence of bulk groups at C-3 and C-5 
positions in some novel 1,4-dihydropyridines 
prepared by Rao et al. confirmed that lipophilicity 
is important for antimicrobial effects. Here again, 
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the results obtained confirmed that compounds with 
a dicarboxylic acid ester moiety at C-3 and C-5 
were less potent than dicarboxamide analogues 
(82). They also showed that 3,5- dicarboxamide 
compounds possessing a para substituent (-OH , -
OCH3 or -Cl) on the C-4 phenyl ring showed high 
inhibitory activities against gram positive and gram 
negative bacteria and fungi. For instance, 17a (ZI at 
100 µg/mL = 24 mm, ZI for Ciprofloxacin = 23 
mm) was found to be highly active against S. 
aureus. 17b (ZI at 100 µg/mL = 26 mm) was 
another potent compound against the same 
bacterium. 17b was also a good antifungal agent (ZI 
at 100 µg/mL = 24 mm against Aspergillus niger, 
for Clotrimazole = 23). Another compound of this 
series, 17c, showed high antifungal activity against 
Chrysosporium Sp. (82) Figure 23. 
 
 
 
NH
NHNH
O O
H3C CH3
N
N
SO2CH3
CH3
                                      R                 Zone of inhibition at 125 g/disc (mm) 
14a+Cloxacillin        p,o-Cl                                     9  
14b+Cloxacillin        o-Cl                              No Inhibition
R R
          
Figure 20. Chemical structures and antibacterial activities of 14a and 14b in combination with Cloxacillin 
 
 
 
NH
NHNH
O O NN
H3C CH3
15a
CH3 CH3
N
NH
NHNH
N N
O O
H3C CH3
15b
N
O
NH3C
O
NHNCH3
  
Figure 21. Chemical structures of 15a and 15b 
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NH
NHNH
O O
H3C CH3
HNH3C CH3
                                                                       Zone of inhibition (mm)
                                          E. coli                             P. vulgaris                       MRSA
16a                              22 (50 g/mL)                   18 (50 g/mL)             10 (1000 g/mL) 
Streptomycin             23 (50 g/mL)                   26 (50 g/mL)             18 (1000 g/mL) 
Tetracyclin                 25 (50 g/mL)                   21 (50 g/mL)             15 (1000 g/mL)
NH
NHNH
O O
H3C CH3CH3 CH3
N
                                                                       Zone of inhibition (mm)
                                          E. coli                             P. vulgaris                       MRSA
16b                              19 (50 g/mL)                   16 (50 g/mL)              8 (1000 g/mL) 
Streptomycin             23 (50 g/mL)                   26 (50 g/mL)             18 (1000 g/mL) 
Tetracyclin                 25 (50 g/mL)                   21 (50 g/mL)             15 (1000 g/mL)     
 
Figure 22. Antimicrobial activity of 16a and 16b  
 
 
NH
NH
O O
H3C CH3
17a           R: Cl
17b           R: OH
17c           R: OCH3
NH
R
  
 
Figure 23. Antimicrobial 1,4-DHPs with bulk groups at C-3 and C-5 positions  
 
In 2011, 1,4-DHPs possessing thiosemi-
carbazide moieties at C-3 and C-5 were subjected to 
antimicrobial studies (83). It was demonstrated that 
these compounds were better antibacterial and 
antifungal agents than 3,5-diester derivatives. 18a 
was found to be highly active against Klebsiella 
pneumoniae and 18b was the most potent 
compound against E. coli according to the 
antimicrobial evaluations. 18a and 18b were also 
both excellent antifungals against Cryptococcus 
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neoformans and Candida albicans, respectively 
(Figure 24). Kumar et al. showed that compounds 
with thiosemicarbazide moieties at C-3 and C-5 
and, at the same time, electron donor substituents (-
OH and -OCH3) on the C-4 position of the phenyl, 
had good inhibitory activities against gram positive 
and gram negative bacteria and fungi (83). 
 
 
NH
NH
O O
H3C CH3
NH
HN HN
R
NH2H2N
S S
                                  Zone of inhibition at 100 µg/mL (mm)
             R       K. pneumoniae    E. coil    C. neoformans   C. albicans
18a    OCH3           18                     -                 24                      -18b     OH               -                     25                 -                       26
Ciprofloxacin       19                    27                 -                        -
Clotrimazole          -                      -                  25                     24
 
Figure 24. Structures of 1,4-DHPs possessing 
thiosemicarbazide moieties at C-3 and C-5 
 
 
 
Kumar et al. also explained the antimicrobial 
activities of structures mimicking the 
thiosemicarbazide moieties at C-3 and C-5 positions 
of 1,4-DHP ring in another report (30). Molecule 19 
was potent against A. niger and C. albicans at 100 
µg/mL (ZI = 17 and 20 mm, respectively; ZIs for 
Clotrimazole were 22 and 18 mm, respectively) 
(84) Figure 25.  
 
NHH3C CH3
19
NN
N N
NN
HS SH
O
NH2H2N
 Figure 25. Chemical structure of compound 19 
 
Solanki et al. demonstrated that the presence of 
bulk substituents on C-3 and C-5 made the 
compound  more potent against bacteria and fungi 
(85). They also concluded that the presence of -Cl 
on the phenyl rings of C-3 and C-5 phenyl 
carboxamide moieties, along with a variation in 
solubility, play an important role in determining the 
antimicrobial activity of the compounds. For 
example, compound 20a possessed effective 
antibacterial activity against Streptococcus 
pyogenes (Figure 26). Akbarzadeh et al. (79,80) 
also e concluded that compounds with a chloro 
group at the meta position of this ring have high 
antimicrobial potency (Figures 19,20). 
Solanki et al. demonstrated that the presence of 
fluoro and nitro groups on any position of the C-3 
and C-5 phenyl carboxamide moieties increases the 
activity, whereas any other group at para reduces 
the activity (20b and 20c) (85) Figure 26.  
 
NHH3C
NH
O
NH
O
NNCl CH3
CH3
R R
                                   Zone of inhibition at 25 µg/mL(mm) 
                 R                                  S. pyogenes  
20a         m-Cl                                     11
20b        m-NO2                                  1220c         p-F                                       12
Chloramphenicole                            13
Ciprofloxacin                                    19
 
Figure 26. Chemical structures and antibacterial 
activities of 20a-c against Streptococcus pyogenes 
 
In 2013 a research group reported the 
antibacterial and antifungal activities of a series of 
C-3 and C-5 diphenyl carbohydrazide derivatives of 
1,4-DHPs (86). The presence of -NO2 and Cl 
groups at the para and ortho positions of 
phenylhydrazine moieties were found to favor 
antibacterial (both gram positive and gram 
negative) and also antifungal activities. 21a, 21b 
and 21c showed half of the activity of Ciprofloxacin 
and more than half of the activity of Ketoconazole 
against S. aureus, E. coli, C. albicans and A. niger 
(Figure 27).    
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NH
NH
O O
H3C CH3
R
                  R             R1        R2
21a      C6H4OH       H          Cl
21b            H            H          Cl 
21c            H            NO2     NO2
NH
HN HN
R2 R1 R1 R2
  
Figure 27. Structures of C-3 and C-5 diphenyl 
carbohydrazide derivatives of 1,4-DHPs 
 
 
Another research group synthesized several C-3 
and C-5 dicarbohydrazide derivatives. Among the 
compounds evaluated for antibacterial activity, 22a 
showed good activity against Bacillus cereus and E. 
coli. The same was true for compound 22b against 
S. aureus and B. subtilis. This compound also 
displayed good antifungal activity against C. 
albicans (87) Figure 28. 
Samaunnisa et al. reported compounds having 
bis pyrazolidine-3,5-dione moieties at C-3 and C-5 
to be antibacterial and antifungal agents but less 
potent than the corresponding phenylhydrazine 
derivatives (88) Figure 29.  
Abu-Melha explained that compounds with 
heterocyclic moieties at C-3 and C-5 positions 
showed better antimicrobial activities than their 
corresponding open chain ones. The tested 
compounds were more active against gram positive 
than against gram negative bacteria. 24a (MIC = 
3.125 µg/mL) was equipotent to Chloramphenicol 
(MIC = 3.125 µg/mL) against B. subtilis and eight 
times stronger than 24b (MIC = 25 µg/mL). The 
structures of these compounds are illustrated in 
Figure 30 (89).  
As previously mentioned, the C-4 substituent 
has a determining effect on the antimicrobial 
activity. In almost all of the reported antimicrobial 
1,4-dihydropyridines the C-4 substituent was a 
(substituted) phenyl ring. It is demonstrated that 
substitution on this ring is important for the 
antifungal activities (90). Compounds including 
OCH3 at para position displayed good inhibitory 
activity against the growth of Aspergillus 
fumigatus, e.g. 25a, but 25b, with -OH instead of -
OCH3, had no inhibitory effect (Figure 31).  
Compounds possessing heterocyclic systems 
substituted with phenyl derivatives have been 
associated with moderate antimicrobial effects. 
Prakash et al. provided a new series of 1,4-DHPs 
and evaluated their antibacterial and antifungal 
activities. The results showed that 26a (Figure 32) 
with CH3 substituent on the phenyl ring of C-4 
pyrazol was the best antibacterial among the studied 
compounds   (MIC = 64 µg/mL against S. aureus; 
Ciprofloxacin: 5 µg/mL). On the other hand, 26b 
without this group was the best antifungal 
derivative (PI of 51.1 and 58.8 against A.niger and 
A. flavus, respectively, while the corresponding 
values for Fluconazole were 81.1 and 77.7, 
respectively) (73). 
In the report provided by Vijesh et al., other 
examples can be found of compounds including a 
pyrazole ring with different substituents on the C-4 
moiety. Among these compounds, 27 showed 
excellent antibacterial activity, and was equipotent 
to Streptomycin, against E. coli, S. aureus and P. 
aeruginosa. The same compounds demonstrated 
poor antifungal activity (74) Figure 33. 
Ahmed et al. reported the antimicrobial 
screening of several 1,4-DHPs against different 
bacteria and fungi. Compounds 28a and 28b shown 
in Figure 34 exhibited good inhibitory activity 
against E. coli, S. aureus and A. Niger, concluding 
that the presence of electron-releasing -OH and -
OCH3 enhances the antimicrobial activity, probably 
by interaction at a receptor site in the 
microorganism through hydrogen bonding. They 
offered confirmation of their conclusion by 
reference to the effects of the drugs such as 
Methicilline and Amoxycilline, which also possess 
-OH and -OCH3 in their structure (91). 
N-1 substitution of the 1,4-dihydropyridines 
which possess heteroaromatic moieties at C-3 and 
C-5 positions was reported by Rajput et al. 
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NH CH3
NH
R O
NH
H3C
O
H2N NH2
                                                    Zone of inhibition at 100 µg/mL (mm)
                 R                     B. cereus     E. coli     S. aureus      B. subtilis     C. albicans
22a      p-Styryl                   12                12              -                      -                       -
22b     p-chlorophenyl          -                   -              12                   11                    10
Streptomycin                     24       No Inhibition     20           No Inhibition            -
Miconazole                          -                   -                -                     -                      17   
Figure 28. The C-3 and C-5 dicarbohydrazide derivatives of 1,4-DHPs and their antimicrobial activity 
 
 
NH
O OR
                                                                Zone of inhibition at 1000 g (mm)
                  R            R1        R2       B. subtilis      E. coli     C.albicans     A. niger
23a      C6H4OH       H         Cl            14                   -                -                    -
23b            H            H         Cl              -                  12               -                    -
23c            H            NO2     NO2          -                    -               14                 12 
Ciprofloxacin (10 g/mL)                 36                  31               -                   -
Clotrimazole (10 g/mL)                    -                    -               29                 25
N NN N
R2
R1
R2
R1
CH3
O O
H3C
O O
  
Figure 29. Antibacterial and antifungal activities of 23a-c  
 
 
 
NHH3C CH3
CH3 NHNNHN
S S
ClCl NHH3C CH3
CH3 OO
ClCl
24a 24b   
 
Figure 30. Chemical structures of 24a and 24b  
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NHH3C CH3
O
O
O
O
CH3H3C
                                  DDAa MIC (g/disc)     MDAb  MIC (g/mL)
               R                                      A. fumigatus
25a      p-OCH3                2.92                               15.62
25b      m-OH             No Inhibition                  No Inhibition
Amphotericin B             0.73                                 1.95
a DDA= Disc Diffusion , b MDA= Microbroth Dilution
R
  
Figure 31. Chemical structures and antifungal activity of 25a and 25b 
 
 
NHH3C CH3
O
O
O
O
CH3H3C
               X
26a        CH326b          H
NN
X
 Figure 32. Structures of compounds 26a and 26b 
 
Antimicrobial evaluation of these compounds 
identified moderate to good antimicrobial activity 
(92), and all were found to be less active against A. 
niger. Compound 29 was more potent than the 
standard against C. albicans. The structure of this 
compound is given in (92) Figure 35.  
The same research group screened more 
compounds for their antimicrobial activity. They 
revealed that compounds 30a, 30b and 30c were 
weak against B. subtilis, E. coli and P. aeruginosa 
but, 30d (Figure 36) showed good antibacterial 
activity against P. aeruginosa, B. subtilis, E. coli 
and S. aureus. All of these compounds were found 
to be more potent than standard antifungal 
(Nystatin) against A. niger. The mean ZI for 30e 
was 19.39 mm and for Nyastatin 9.53 mm, both at 
100 µg/mL (93).  
It seems that the presence of a thiazolidinone 
moiety favors antifungal activity, while compounds 
with isoxazole rings at the same positions show 
poor potency against A. niger (92,93).   
Mithlesh et al. reported the preparation and 
high antibacterial and antifungal activities of a 
series of 1,4-dihydropyridine derivatives. 
Compounds 31a and 31b, shown in Figure 37 
exhibited very high antibacterial and antifungal 
potencies. It was concluded that the nitro group, 
with its lone pair of electrons, plays an important 
role in the antimicrobial activity by forming 
complexes with microbial metaloenzymes (94). 
N-1 phenyl substituted 1,4-dihydropyridines 
which have another phenyl ring substituted on the 
C-4 moiety, bearing substituents on both phenyl 
rings have been subjected to antimicrobial 
evaluations. All the compounds with a chloro group 
substituted on the N-1 phenyl ring were better 
antibacterials than antifungals. 32a inhibited P. 
vulgaris growth with a 21 mm zone of inhibition 
(Amoxicillin = 25 mm). Compound 32b was almost 
as strong as amoxicillin against E. coli (ZI = 23 
mm, for Amoxicillin = 25 mm). Replacing the 
para-chloro group in 32c with para-OCH3 caused a 
change in the antimicrobial potency in favor of 
antifungal activity. 32d inhibited A. Niger growth 
with 23 mm zone of inhibition, while Griseofulvin, 
as the standard drug, had ZI = 24 mm (95) Figure 
38. 
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NHH3C CH3
O
O
O
O
CH3H3C
NHN
Cl
                                                                 Zone of inhibition at 1 g/mL (mm)
                           E. coli      S. aureus       P. aeruginosa      A. flavus     C. keratinophilum     C. albicans
27                          17              15                       16                      2                        3                            4
Streptomycin       16              15                       16                    13                      17                          22   
Figure 33. Chemical structures and antimicrobial activity of compound 27 
 
 
NHH3C CH3
RO OR
O
                                                                     Zone of inhibition at 50 g/mL (mm)
                     R                  R1                 S. aureus     E. coli       A. niger      C. albicans
28a           OC2H5           p-OH                14               11               12                    10
28b           OC2H5        p,m-OCH3              11               10               12                      9
Gentamicin                                            20               19                -                        -
Fluconazole                                             -                   -               18                    18
O
R1
  
Figure 34. Chemical structures and antimicrobial activity of 28a and 28b 
 
 
NCl Cl
O
NN
O
                 Zone of inhibition at 100 g/mL (mm)
                                      C. albicans
29                                      9.57
Nyastatin                         9.53   
Figure 35. Structure of 29 and its antifungal activity against C. albicans 
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NCl Cl
N
SS
N
                     R                    R1
30a            p-OCH3          p-CH3
30b           m-Cl                p-CH3
30c           p-OCH3            p-Cl
30d               H                  p-Cl
OO
R1R1
R
 Figure 36. Chemical structures of some antimicrobial N-1 substituted 1,4-dihydropyridines 
 
 
 
ANTICANCER ACTIVITY 
 
One of the major clinical problems during 
antitumor chemotherapy is the development of 
multidrug-resistance (MDR) in tumor cells (96). 
MDR is defined as the increased efflux of a broad 
class of hydrophobic cytotoxic drugs mediated by 
one of a family of energy-dependent transporters, 
known as ATP-binding cassette (ABC) transporters. 
Several members of the ABC transporter family, 
such as P-glycoprotein (P-gp, also known as 
MDR1), can induce multidrug-resistance. 
Researchers have worked to develop drugs that 
either evade efflux or inhibit the function of efflux 
transporters. A large number of structurally diverse 
compounds have been identified as MDR inhibitors 
(98). These compounds in general have aromatic 
moieties in their structure, are highly lipophilic and 
possess monocationic or dicationic side chains. 
Most of them also have a protonated nitrogen group 
at physiological pH. 
Because of their affinity for P-gp, 1,4-
dihydropyridines have become the most extensively 
investigated compounds as P-gp inhibiting agents 
(98). It is interesting that 1,4-DHPs which lack 
calcium antagonistic activity or are weak calcium 
channel blockers possess this property (98-100). In 
addition, the presence of a hetaryl group at 4-
position of DHP was found to be effective at 
increasing MDR-inhibiting activity (101). The 
literature shows that the type of C-3, C-4 and C-5 
substituents and also the lipophilicity of the 
molecule have important effects on the anticancer 
activity of 1,4-dihydropyridine compounds.  
Based on QSAR/QSPKR (quantitative 
structure-activity/pharmacokinetics relationship) 
prediction models, 1,4-DHPs with potent P-gp 
inhibitory effects and minimal Ca2+ channel 
blocking activity have been reported. The results 
suggested LogP as a highly correlated parameter 
with P-gp inhibitory effect in Daunomycin 
cytotoxicity (102). 
Tasaka et al. (2001) reported MDR-reversing 
symmetric 1,4-dihydropyridines possessing an n-
pentyl group at the C-4 position. Based on Ford et 
al., compounds with one or more tertiary amino 
groups had a strong MDR-reversing effect and a 
cyclic amine was more effective than a noncyclic 
one (103). Compounds with these characteristics 
were designed for the investigation by Tasaka et al. 
(104). Some of the results are summarized in Figure 
39. The reported resistance index was determined 
from the IC50 of Doxorubicine (DXR) with the test 
compounds (1 µg/mL) in KB/VJ300 cells divided 
by the IC50 of DXR without test compounds in the 
KB cells. Antitumor activity was determined by the 
survival days of mice treated with Vincristine 
(VCR) (0.1 µg/kg, ip) with the test compounds (100 
µg/kg, ip) divided by the survival days of mice 
treated by VCR (0.1 µg/kg, ip) alone. 
The results showed that 33a had no antitumor 
activity, presumably because it lacked a tertiary 
amino group. 33b and 33c were effective antitumor 
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agents; 33b was a better MDR-reversing compound 
according to the resistance index values obtained. 
Replacement of one of the 3-pyridylpropylesters 
with a substituted piperazinylpropyl group provided 
compounds with lower resistance index values in 
vitro and in vivo, amongst which 33d showed the 
best activity. 33e indicated that the nitrogen atom at 
the 2-position in 2-pyridylpropylester is probably 
sterically hindered and therefore less effective than 
3- or 4-pyridylpropylesters. Compound 33f revealed 
that substitution by 4-pyridylpropylester was 
associated with high MDR activity. Compounds 
such as 33b and 33e, with weak calcium 
antagonistic activities showed effective MDR-
inhibiting activities both in vitro and in vivo. In 
particular, 33e was expected to be the most suitable 
compound to overcome MDR (104). 
 
NR R
S N
NO2
O
O
O
O
N(CH3)2
                                                                        Zone of inhibition at 200 g/mL (mm)         
               R            P. aeruginosa      S. aureus         M. leutius          K. rosea        A. candidus        A. niger     
31a         CH3                    21                     20                     25                     20                     20                     2231b       OEt                 24                     19                     27                     22                     22                     24
Gentamicin                24                     18                     35                     24                      -                        -
Ampicilline                  -                        -                        -                       -                      30                      32
H3C CH3
  
Figure 37. Antibacterial and antifungal activities of 31a and 31b 
 
NH3C CH3
O
O
O
OR R
O
F
Cl
                R            R1
32a        C2H5       o-Cl
32b        CH3        m-Cl
32c        C2H5       p-Cl
32d        C2H5      p-OCH3
R1
  
Figure 38. Structures of N-1 substituted 1,4-DHPs with antibacterial and antifungal activities 
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NHH3C CH3
CH3
OR
O
O R
O
NHH3C CH3
CH3
ON
O
N
O R
O
N
N
N
CH3
         
33a
33b
 
33c
R
N
N
N
33d 
33e 
33f
R
  
Figure 39. Chemical structures of 1,4-dihydropyridines possessing an n-pentyl group at the C-4 position 
 
 
In another study, asymmetric compounds with a 
bulk group at C-3 position were synthesized and 
their P-glycoprotein-inhibitory activities were 
evaluated in human breast cancer MCF-7 cells. 
These compounds restored the intracellular drug 
accumulation by inhibiting P-glycoprotein efflux 
activity. For instance, compounds 34a and 34b 
demonstrated a 15-fold increase in Vinblastine 
accumulation in P-glycoprotein-overexpressed 
MCF-7/adr cells. Pyridine derivatives such as 35a 
and 35b demonstrated stronger inhibitory effects 
than the corresponding 1,4-dihydro analogues, 34a 
and 34b. Thus, the oxidation of the 1,4-
dihydropyridine ring to the corresponding pyridine 
may favor P-glycoprotein interaction (105). Results 
from the Daunomycin cytotoxicity assays were in 
agreement with those from the Vinblastine 
accumulation assays. The IC50 values in Figure 40 
are the inhibitory concentrations of Daunomycin in 
the presence of 3 µM of the studied 1,4-
dihydropyridines or Niguldipine. 
In 2002, Kawase et al. investigated the MDR-
reversal activities of 3,5-dibenzoyl-1,4-
dihydropyridines against mouse lymphoma cells 
transfected with human MDR1 gene. They also 
studied the cytotoxic activity of the compounds 
against human oral tumor cell lines. The 
compounds demonstrated very variable cytotoxic 
activity against HSC-2 and HSG tumor cell lines. 
This variation was dependent on the difference in 
the substituents at the C-4 position. Compounds 36a 
and 36b displayed the highest cytotoxic activity 
against HSC-2 (IC50 = 7.0 µM) and HSG (IC50 = 8.7 
µM) (Figure 41). Cytotoxicity was nearly the same 
as that of Doxorubicine (IC50 = 4.1 µM and 5.3 µM, 
respectively). 36a was found to be more active than 
the others. It seems that Cl substitution at metha 
position on the phenyl ring leads to a higher 
cytotoxic and MDR-inhibiting activity than that at 
the ortho or para positions. However, metha-Br 
derivative 36c was inactive (5). Lipophilicity was 
one of the most important parameters affecting 
MDR-modulating efficiency in the structure-
activity relationship studies of MDR-modulating 
drugs (98). The LogP values of molecules were 
calculated and found to be higher (LogP = 4.26–
7.47) than the corresponding values of Verapamil 
(LogP = 3.71) or Nifedipine (LogP = 2.35). It was 
also mentioned that lipophilicity alone was not an 
essential parameter of direct MDR-modulating 
activity of this series of compounds (5). 
Morshed et al. reported that compounds 36a 
and 36b from the above research had higher 
cytotoxicity against the tumor cell lines (HSC-2, 
HSC-3, HSG, HL-60) than normal cells (HGF, 
HPC, HPLF), yielding a tumor specific (TS) 
cytotoxicity value of >33 and >53, respectively. 
Western blot analysis showed that 36a and 36b 
transiently increased the expression of both the anti-
apoptotic protein (Bcl-2) and pro-apoptotic proteins 
J Pharm Pharm Sci (www.cspsCanada.org) 18(1) 1 - 52, 2015 
 
 
 
20 
(Bax, Bad) at lower concentrations (2.5-40 µM), 
and reduced their expression at higher 
concentrations in HL-60 cells (6) Figure 41. They 
concluded that 3,5-dibenzoyl-1,4-dihydropyridines, 
such as 36a and 36b, with both MDR reversal 
activity (5) and tumor-specific cytotoxicity, may be 
possible antitumor candidates (6). 
Another research group explained the 
antiproliferative effects of 1,4-dihydropyridine 
derivatives in comparison with those of Verapamil 
(VP) and Doxorubicin. The human breast cancer 
T47D cell line and its MDR1 over-expressed and 
moderately resistant cells (RS) were used in this 
research. They also examined the effects of these 
compounds on cytotoxicity of Doxorubicin in these 
two cell types. The cytotoxicity of the molecules 
was similar to that of Verapamil, and significantly 
less than that of Doxorubicin. Among these 
compounds, 37a and 37b showed promise as 
potential new MDR1 reversal agents (106) Figure 
42. 
Thiosemicarbazide derivatives of 1,4-
dihydropyridines had significant antitumor activity 
(107). Kumar et al. explained the anticancer activity 
of a new series of 1,4-dihydropyridine derivatives 
against HepG2 and Hela cancer cell lines. 
Compound 38a was more active than the other 
compounds against HepG2 and MCF-7. Likewise, 
38b was more active than the other molecules 
against Hela cancer cells (108) Figure 43. 
 
 
NHH3C CH3
O
OH3C
                                      R             IC50 (M) (MCF-7)34a+Daunomycin     p-O-nPr           0.79
34b+Daunomycin    p-O-nBu           0.92
Niguldipine+Daunomycin               1.09
O
O
N
R
NH3C CH3
O
OH3C
                                         R             IC50 (M) (MCF-7)35a+Daunomycin       p-O-nPr           0.52
35b+Daunomycin      p-O-nBu           0.61
Niguldipine+Daunomycin                 1.09
O
O
N
R
  
 
Figure 40. Structures and anticancer activity of 34a, 34b, 35a and 35b in combination with Daunomycin 
 
 
 
NH
O
                     R       36a            m-Cl
36b            o-CF3 36c            m-Br
O
O
O
R
H3C CH3
  
Figure 41. Anticancer 3,5-dibenzoyl-1,4-dihydropyridines 
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NH
O
                                                                IC50 (M)    
                     R1                       R2         T47D        RS
37a      o-methyl                phenyl       113          141
37b      o-chlorophenyl      methyl       121          126
DXR                                                    0.399       0.545
VP                                                        123          108
36a+DXR                                            0.296       0.327
36b+DXR                                            0.267       0.288
VP+DXR                                             0.267       0.316
S
N
R1
R2
O
CH3H3C
R2
  
Figure 42. The antiproliferative effects of 37a and 37b in combination with Verapamil and Doxorubicin 
 
 
NHH3C CH3
O
NH
HN NH
HN
O
NH2
X X
OH
O CH3
                                           GI50a (M)
            X              HepG2         MCF-7        Hela 
38a      O                 31.2              32.3   -    
38b      S                   -                    -               31.1 
Doxorubicin          0.01  0.02             0.05
a Values reported in GI50: concentration (M) of compound
  causing 50% inhibition of cell growth
H2N
  
Figure 43. (Thio)semicarbazide derivatives of 1,4-DHPs and their antitumor activity 
 
 
 
The structural requirements of 1,4-dihydropyridines 
for MDR reversal were also investigated using the 
molecular docking technique on multidrug 
resistance protein 1 (MRP1). Sirisha et al. subjected 
a series of 1,4-DHP derivatives to MDR inhibiting 
activity assessment and molecular docking studies.  
It was observed that only two test compounds, 39a 
and 39b, induced inhibition of MRP1 basal ATPase 
activity at concentrations above 10 µM. Compound 
39b was shown to be relatively more potent than 
39a according to the docking results. The structures 
of these compounds and the experimental and 
computational results are provided in Figure 44. 
The IC50 values corresponding to the inhibitory 
concentration of the compounds against the MRP1 
and Ki values are the in silico calculated inhibitory 
concentrations. A correlation between docking 
scores and experimental binding data suggested that 
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this technique might be useful for developing a 
pharmacophore model to help interpret the affinities 
observed and to design new MRP1 antagonists 
(109). 
 
NHH3C CH3
O
NH
O
                                                 IC50 (M)        Kia (M)
             X              Ar                           MRP1
39a      CH        o-furyl                20                  0.95
39b       N          o-pyrrolyl          14                  0.66
Benzbromarone                           4                  0.19
a Ki= Inhibition Constant
NH XX
Ar
 
Figure 44. Experimental and computational values for 
the inhibition of MRP1 by 39a and 39b 
 
 
Inhibition of the MDR reversal activity of 1,4-
dihydropyridine derivatives using a multidrug-
resistant human colon cancer cell line expressing 
MDR1/LRP and a human mdr1 gene-transfected 
mouse lymphoma cells was reported by Engi et al. 
The tumor-specific cytotoxicity of these compounds 
against human tumor and normal cell lines was also 
investigated. Compound 40a displayed a marked 
inhibition of the MDR of mouse lymphoma cells. 
40b had a very strong tumor-specific cytotoxic 
action, with TS (CC50 normal/ CC50 tumor) of 5.9 
µM (TS of Doxorubicin was >14.6 µM). The 
dihydropyridine derivatives were more cytotoxic 
against tumor cell lines as compared with normal 
cell lines (110) Figure 45. 
 
NH
R2
H3C CH3
NH
OR1
NO2
                  R1                R2           
40a       o-OCH3         CN
40b       o-OCH3         COOC2H5  Figure 45. Chemical structures of 40a and 40b 
 
 
Evaluation of the antiproliferative effects of a 
series of new imidazole-substituted indeno[1,2-
b]quinoline-9,11-dione derivatives on HeLa, 
LS180, MCF-7 and Jurkat human cancer cell lines 
was reported in 2013. These molecules showed 
more activity against the Jurkat cell line than the 
LS180, MCF-7 and Hela cell lines. It was 
concluded that compounds bearing an imidazole-2-
yl moiety at the C-11 position of DHP have 
stronger antiproliferative activity than Cisplatin 
against the Jurkat cell line. Also the presence of 
electron-withdrawing groups on the imidazole ring 
increased the antiproliferative potential of the 
molecules (111) Figure 46. 
 
1,2,3,4-TETRAHYDROPYRIMIDINES 
ANTITUBERCULAR ACTIVITY 
 
As mentioned above, 1,2,3,4-tetrahydropyrimidines 
share many biological properties with 1,4-
dihydrpyridines. 1,2,3,4-THPMs and some full 
aromatic pyrimidine derivatives have also shown 
antitubercular activities. Structural features 
affecting the antitubercular potency of these 
compounds are the nature of C-2, C-4 and C-5 
substituents and also the lipophilicity of the 
compound. Most of the reported antitubercular 
1,2,3,4-THPM derivatives have one of the general 
structures shown in Figure 47. 
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N
O O
CH3
CH3
R
                                                                  IC16 (M)
               R          R1            Hela        LS180      MCF-7         Jurkat
41a         H      3-NO2            9.2           12.5           >25                0.7
41b        Ph     3,4-di-Cl      10.7           19.4          13.6                1.7
Cisplatin                              5.6             5.0            4.0                1.9
NNH3C
R1
 Figure 46. Fused-ring anticancer 1,4-DHPs 
 
 
NH
NHArHN
Ar
H3C X
O
NH
NHRO
Ar
H3C X
O
 Figure 47. Structural categories of antitubercular 1,2,3,4-THPMs 
 
Carbonyl and thiocarbonyl groups are the most 
common types of functional groups in the C-2 
position of 1,2,3,4-THPM derivatives. As with 1,4-
DHPs, substituted phenyl and heteroaromatic rings 
have been studied as the C-4 substituents of both 
1,2,3,4-THPMs and pyrimidine derivatives. Both 
the 5-phenylcarboxamide and 5-alkylcarboxylate 
esters of the 1,2,3,4-THPM scaffold have been seen 
to possess antitubercular properties (13,112-116).  
Based on the structures of the active 
derivatives, lipophilicity seems to be an important 
physicochemical property affecting the compound's 
potency. However, the lipophilicity of the 
substituents at any position of the molecule cannot 
be considered the only determining factor. 
Regarding the C-2 substituent, no specific 
relationship between the potency and the type of 
this substituent (carbonyl or thiocarbonyl) can be 
found. For example, compound 42a (MIC = 16 
µg/mL) was more potent than 42b, with an MIC of 
32 µg/mL, but 42c (MIC = 32 µg/mL) was as 
potent as 42d, while 42e (MIC = 0.25 µg/mL) was 
weaker than 42f (MIC = 0.125 µg/mL) as reported 
by Yadlapalli et al. The minimum inhibitory 
concentration of Isoniazid was determined to be 
0.03µg/mL by the same author (13) Figure 48. The 
same is true for the report of Trivedi et al. (114), 
who also changed the thiocarbonyl to a thiomethyl 
moiety, observing a decrease in the potency of most 
of the compounds, which did not agree with the 
increase in their lipophilicity values.   
The C-4 derivatives are lipophilic aromatic or 
heteroaromatic moieties and it seems that the 
amount of this physicochemical property affects 
potency. This can be exemplified by the two THPM 
derivatives illustrated in Figure 49. Compound 43a 
with LogP = 4.77 was more potent than 43b (LogP 
= 4.27) (115).  
The position of the substitution on the C-4 
phenyl moiety was discussed by Virsodia et al. 
(115). Substituted N-aryl-6-methyl-2-oxo-4-phenyl-
1,2,3,4-tetrahydro-pyrimidine-5-carboxamides 
which had antitubercular activity were subjected to 
a 3D-QSAR study by this group, who concluded, 
from the CoMFA electrostatic contours, that 
electropositive groups are favored at the ortho', 
meta and para positions of the 4-phenyl ring. The 
substitution pattern of these compounds is 
illustrated in Figure 50. 
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               X42a         O
42b         S
NH
NHO
H3C X
O
NN
H3C
             X
42e       O
42f        S
Cl
NH
NHNH
H3C X
O
NN
             X
42c       O42d       S
NH
NHO
H3C X
O
NN
H3C
  
Figure 48. Molecular structures of 42a-f 
 
NH
NHNH
H3C O
O
Cl
F
Cl
43a
NH
NHNH
H3C O
O
NO2
F
43b
             PI at > 6.25 g/mL
43a                     48
43b                     24
Rifampicin        99             
  Figure 49. Chemical structures and PIs of antitubercular 1,2,3,4-THPMs  
 
 
 
NH
NHNH
H3C O
O
Ar
o'
m'
p
m
o
 Figure 50. The substitution pattern of substituted N-aryl-
6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro pyrimidine-
5-carboxamides 
 
 
They also indicated that electronegative groups 
at the meta position of this ring increase the 
activity. Using the CoMSIA electrostatic contours, 
they confirmed that electropositive groups are 
favored at the para and ortho positions of the 4-
phenyl ring. According to the CoMFA steric fields 
and steric CoMSIA contours reported by this group, 
bulky substituents are not favored at the para 
position of the 4-phenyl ring. Mapping the desired 
and undesired hydrophobic regions on this ring, 
they demonstrated that hydrophobic groups at the 
meta' and para positions decrease the activity. 
Hydrogen bonding with an H-bond donor at the 
meta' and para positions of the 4-phenyl ring was 
also confirmed to be favorable (115).    
Between the 5-phenylcarboxamides and 5-
alkylcarboxylate esters of the 1,2,3,4-THPMs 
scaffold, the latter derivatives proved to have 
superior antitubercular properties. For example, 42f 
was 256 and 42e was 128 times more potent than 
42c and 42d, respectively (13) Figure 48. A smaller 
difference in the magnitude of the activity was 
mentioned in the report of Zalavadiya et al. (116). 
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5-Alkylcarboxylate ester 44a exhibited a growth 
inhibition percentage of 65, which was stronger 
than that for the corresponding phenylcarboxamide 
derivative, 44b, with a growth inhibition percentage 
of 3.0, while Rifampicin, as the standard drug, 
showed a growth inhibition percentage of 98, all at 
6.25 µg/mL (Figure 51). The results of other 
research articles confirm the higher potency of the 
ester derivatives (114).  
 
N
NH
H3C O
O
OH3C
O CH3
44a
N
NH
H3C O
O
NH
O CH3
44b
H3C
 
Figure 51. Chemical structures of 44a and 44b 
 
 
The 3D-QSAR study by Virsodia et al. also 
clarified some structural features of the 5-
phenylcarboxamide moiety and its influence on 
potency. According to the CoMFA electrostatic 
contours obtained in this study, electropositive 
groups are favored at the meta position of the 5N-
phenyl ring. The CoMSIA electrostatic contours 
favored the electronegative groups at the para 
position of this ring. The CoMFA steric fields 
confirmed meta position on the 5N-phenyl moiety 
as the favored position for bulky substituents. Using 
hydrophobic contours of CoMSIA, Virsodia et al. 
indicated that hydrophobic groups positioned at 
meta' decrease the activity, but small hydrophobic 
groups are accepted at the meta position of the 5N-
phenyl ring (115). This latter observation can be 
better understood by comparing 45a and 45b. As 
can be seen, the small hydrophobic methyl group is 
not tolerated at meta' position in 45a, but the same 
group in the meta position of the 5N-phenyl ring 
lends higher activity to the compound (Figure 52). 
H-bond acceptor groups were disfavored in the 
ortho and meta positions of the ring.  
Full aromatic analogues of Biginelli 
pyrimidines have also shown antitubercular 
activities, but weaker compared with the 1,2,3,4-
THPMs (113). 46a and 46b shown in Figure 53 are 
two examples of such weak antitubercular 
compounds. 
N-1 substitution on both 5-phenylcarboxamide 
and 5-alkylcarboxylate esters of 1,2,3,4-THPMs led 
to weak to moderate compounds (116) Figure 54. 
Ring fusion to the C5=C6 bond of the 
tetrahydropyrimidine moiety (reported by Trivedi   
et al.) led to some pyrazolo[3,4-d]pyrimidines being 
regarded as promising antiTB compounds (114) 
Figure 55.  
 
ANTIMICROBIAL ACTIVITY 
 
Microbial infections comprise a group of diseases 
that have been common since the beginning of 
humankind. Even with the enormous achievements 
that have been made in the field of antimicrobial 
medications, there is still no perfect solution to 
many of the deadly diseases caused by bacteria 
(117). 
 
 
o
m
p
m'
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NHNH
H3C O
O
O
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CH3
CH3
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NHNH
H3C O
O
O
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CH3
H3C
  
Figure 52. Molecular structures of 45a and 45b 
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N
NO
H3C NH
O
H3C
OH N
NO
H3C NH
O
H3C
46b
                         MIC (M)
46a                       > 128
46b                       117.7
Moxifloxacin         0.47
Isoniazid                0.12
46a
  
Figure 53. Full aromatic analogues of Biginelli pyrimidines and their antitubercular activity 
 
  
N
NHO
H3C
O
H3C
47b47a
O
Cl
F
F
N
NHNH
H3C
O
O
Cl
F
OH
H3C
               PI at 6.25 g/mL
47a                   74
47b                   46
Rifampicin      98   
Figure 54. Antitubercular activity of N-1 substitututed 5-phenylcarboxamide and 5-alkylcarboxylate esters of 1,2,3,4-
THPMs 
 
 
Several reports of antimicrobial activities of 
substituted 2 – oxo / thioxo – 1 , 2 , 3 , 4 -
tetrahydropyrimidines have been published in the 
recent years (118-142). For example, Sawant et al. 
described the antimicrobial activity of some THPM 
derivatives in 2008. They screened them against the 
gram-positive bacteria, S. aureus, and observed that 
two of the compounds, 49a and 49b, were more 
effective than others. The structures of these 
compounds are illustrated in Figure 56. The same 
research group also investigated the results using 
the QSAR approach and observed a good 
correlation between the structural features and 
biological activity. They concluded that molecules 
with a less positive partial charge and a negative 
polar Van der Waals surface area make a higher 
contribution rather than the ratio of Van der Waals 
surface area to molar refractivity (119).  
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N
NN
N NH2
NN
Cl
R
                                R                        MIC (g/mL)
48a                o-chlorophenyl                   1.20
48b               p-methylphenyl                   1.20
Isoniazid                                                  0.20   
Figure 55. Fused ring 1,2,3,4-THPMs and their antitubercular activity 
 
 
Another series of THPM derivatives with a 
group substituted at N-3 providing higher Van der 
Waals surface area, as compounds 49a and 49b, and 
different groups at C-2, C-4 and C-5 positions, were 
screened against gram negative (E. coli and 
Salmonella typhi) and gram positive (S. aureus and 
B. subtilis) microorganisms. Compound 50a 
showed good activities against S.aureus, B. subtilis, 
E. coli and S. typhi (MICs = 3, 1, 1 and 2 µg/mL, 
respectively). Chloramphenicol was used as one of 
the standards in this study. The corresponding MIC 
values for this drug were 5, 7, 6 and 7 µg/mL. 
Compound 50b was also a good inhibitor of S. typhi 
growth, with an MIC = 3 µg/mL. It was concluded 
that compounds which had OCH3 and/or Cl 
substitution at any position of the C-4 phenyl group 
showed antimicrobial activities at lower 
concentrations (117) Figure 57.  
 
NH
N
H3C O
O
O
                    R               R1
50a            OCH3        OCH3
50b            OCH3          Cl
R
O
R1
H3C
CH3
  
Figure 57. Chemical structures of 50a and 50b 
A substituted benzoyl methyl thio group located 
on the C-2 position of the THPM ring seemed to be 
effective in the antimicrobial activity, as effective 
as a moiety located on N-3 position. Hussein et al. 
revealed that the most active compounds of this 
series contained an electron-withdrawing group (R1 
= Cl, Br; R2 = Br, Cl or NO2) in their structures, 
while the least active ones contained an electron-
donating group (R1 = H, CH3; R2 = OCH3, CH3). 
51a was effective against S. aureus, E. coli and P. 
aeruginosa, while 51b (Figure 58) had 
antimicrobial activity against B. cereus, E. coli and 
P. aeruginosa (120). 
An investigation into compounds with bulk 
moieties at C-4, or C-5 or a heterocyclic ring fused 
to the 1,2,3,4-THPM ring (Figure 59) revealed 
variable antimicrobial activities ranging from zero 
to moderate (121). 
Tetrahydropyrimidines possessing bulkier 
groups at C-4 position were also subjected to 
antimicrobial assessments. Different examples of 
these structures will be discussed below. 
Nagawade et al. described the antibacterial 
activity of a series of THPMs with substituted 
biphenyl ring against both gram positive and gram 
negative strains. Most of the compounds (e.g. 
compound 55) displayed moderate activity against 
the studied strains, while all the tested compounds 
were inactive (MIC > 32 µg/mL) against P. 
aeruginosa and Enterococcus faecium, unlike the 
standards (Ciprofloxacin, Sparfloxacin, and 
Trovafloxacin) (122) Figure 60. 
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NH
N
H3C O
H3C
OO
49a
OH3C
NH
N
H3C S
O
OO
49b
H3C
                 MIC (g/mL)
                    S. aureus
49a                  32
49b                  32   
   Figure 56. Chemical structures of 49a and 49b and their antibacterial activity against S. aureus 
 
 
NH
N
H3C S
OH3C
O
                                                                          Zone of inhibition at 100 mol/mL (mm) 
                         R1                  R2               S. aureus       E. coli         P. aeruginosa    B. cereus 
51a                  Cl                    Br                  23                  22                       21                 -
51b                  Br                   NO2                -                    21                       20                25
Chloramphenicol                                        27                  30                       24                32
R1
O
R2
  
Figure 58. Chemical structures and zones of inhibition at 100 µmol/mL (mm) for 51a and 51b  
 
 
The replacement of one of the C-4 position phenyl 
rings by tetrahydropyran or tetrahydropyrrolidine 
led to compounds with high antimicrobial activity. 
For example, 56a and 56b had significant activity 
against the selected bacteria and fungi, with zones 
of inhibition almost comparable to those of the 
standard drugs (Figure 61). It is interesting that the 
substituted 4-diethylaminophenyl compounds (56c 
and 56d) were also as potent as their closed-ring 
analogues 56a and 56b (123). 
1,2,3,4-tetrahydropyrimidin-2(1H)-ones having 
a substituted urea on the C-4 phenyl group have 
been evaluated for antibacterial and antifungal 
activities against various gram positive and gram 
negative bacteria as well as fungal strains. These 
compounds were similar to the molecules studied 
by Nagawade et al. (122) but differed in their C-4 
substituent. The antibacterial activity data suggested 
that the presence of lipophilic moieties or H-bond 
acceptors such as F, Cl, CF3, OCF3 and OCH3 at 
ortho position of the C-4 substituent favors high 
antibacterial activity (Figure 62). 
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NH
NH
H3C O
OH3C
O O CH3
NH
NH
O
N
NH
H3C
O CH3
NH
NH
H3C O
H3C O
O
OH
N N2
                                              Zone of inhibition at 1mg/mL (mm)
                C. albicans    B. subtilis    B. cereus   E. coli     P. aeruginose     S. aureus
52                 14                    12                -               -                   -                        -
53                 15                      8                8              3                   -                       3         
54                 15                      2                9              -                   -                        -
Ref.              44                     40              30            20                 35                     50
52 53 54
  
Figure 59. Bulk moieties at C-4, or C-5 or a heterocyclic ring fused to the 1,2,3,4-THPM and the corresponding 
antimicrobial activities 
 
 
NH
NH
H3C S
                                                                          MIC (g/mL) 
                                 S. aureus      E. coli        S. epidermidis       Klebsiella sp.        E. faecalis
55                                   8                  8                        8                         8                            8
Ciprofloxacin               1                  0.007                 1                         0.01                       2
Sparfloxacin                 1                  0.007                 1                         0.01                       1
Trovafloxacin               0.5               0.002                 0.5                      0.025                     1
OH3C
O
O CH3
O
  
Figure 60. Chemical structure and antibacterial activity of compound 55 
 
 
Compounds 57a and 57b, both with MIC=10 
µg/mL against S. aureus, and E. coli are good 
examples. Ciprofloxacin, which was used as the 
standard, had an MIC of 25 and 15 µg/mL against 
the same bacteria, respectively). But substitution at 
meta position or disubstitution  at meta and para 
positions of the C-4 substituent led to moderate (or 
even no) activity with respect to the standard drug 
against the test strains. Compound 57c had no 
activity against E. coli up to 200 µg/mL and was a 
moderate antibacterial against S. aureus (MIC=90 
µg/mL). The presence of nonpolar lipophilic groups 
such as isopropyl or n-butyl at the C-4 terminal 
phenyl ring had no major effect on the activity (e.g. 
57d with MIC=85, 55 and 95 µg/mL against S. 
aureus, E. coli and Salmonella typhimurium, 
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respectively). The structure-activity relationships 
(SAR) of the molecules for antibacterial activity 
strongly correlated with their SAR for antifungal 
activity. For instance, MIC values of µg/mL against 
C. albicans, A. niger and A. flavus were observed 
for 57a. In the case of Miconazole, which was used 
as reference drug, the MICs were 25, 20 and 20 
µg/mL against C. albicans, A. niger and A. flavus, 
respectively (124). 
Other compounds with bulk groups at C-4 
position of the THPM ring containing a rotatable 
bond were reported by Balaji et al. Among the 
tested compounds, 58 was the most active against S. 
aureus, B. cereus, E.coli, and P.aeruginosa (125) 
Figure 63.  
THPMs containing a naphthalene ring as the C-
4 substituent have also been investigated for their 
antimicrobial properties. According to a report by 
Borse et al., such compounds are not strong 
antimicrobials. The best reported compound, 59, 
shown in Figure 64, had an MIC=250 µg/mL 
against four representative pathogens: E. coli, P. 
neumoniae, A. niger and C. albicans. Streptomycin 
was the standard drug used in the antibacterial 
assays, with MIC=125 μg/mL, while Fluconazole 
was the standard antifungal agent 
(MIC=125μg/mL) (126). 
 
 
NH
NH
H3C
O
O
                                                                Zone of inhibition at 100 ppm (%)
                                R        X           S. aureus            E. coli        A. niger         H. oryzae
56c                       C2H5      S              23                      22                 19                  1556d                       CH3       NH                21                      21                 20                  19Penicillin                                            20                      20                  -                     -
Griseofulvin                                        -                         -                  20                  20
O
R
N
OH
NH
NH
H3C
O
O
                                                                Zone of inhibition at 100 ppm (%)
                                R                  S. aureus            E. coli        A. niger         H. oryzae
56a                       C2H5                   23                      23                 21                  2056b                       CH3                           23                      23                 18                  19Penicillin                                         20                      20                  -                     -
Griseofulvin                                     -                         -                  20                  20
O
R
N
  
Figure 61. Chemical structures and antimicrobial activity of 56a-d 
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NH
NH
H3C S
NH
OH3C
O
O
NH
                         R
57a                  o-F
57b                 o-Cl
57c             m,m'-F          
57d           p-isopropyl
R
  
Figure 62. 1,2,3,4-THPMs having a substituted urea on the C-4 phenyl group  
 
 
NH
NH
H3C O
O
OH3C
O
N
Cl
O CH3
                                            Zone of inhibition at 250 g/mL (mm) 
                            S. aureus         B. cereus          E. coli       P. aeruginosa
58                            15                     15                    13                   14
Streptomycin         17                     17                    16                   15   
Figure 63. Chemical structure and antimicrobial activity of 58 
 
 
NH
NH
H3C O
O
O CH3
OH3C
59   
Figure 64. 1,2,3,4-THPM containing a naphthalene ring at the C-4 position 
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Adhikari et al. explained the antimicrobial 
activity of THPMs substituted by quinoline at C-4 
position. These compounds were all stronger than 
the naphthalene analogues and showed moderate to 
good antimicrobial activities. Compound 60 showed 
good activity against E. coli, P. aeruginosa, S. 
aureus, C. albicans and A. flavus with zones of 
inhibition of 20, 19, 16, 18 and 20 (all at 100 
µg/mL), respectively (Figure 65). The 
corresponding values for the standard drug 
(Chloramphenicol) were 19, 18, 16, 20 and 21 (all 
at the same concentration), respectively (127). 
 
NH
NH
N
60
SH3C
O
OH3C
OH
 Figure 65. 1,2,3,4-THPM containing a quinoline moiety 
at the C-4 position 
 
 
 
Two 1,2,3,4-tetrahydropyrimidin-2(1H)-one 
(thione) scaffolds attached through a phenylene 
linker were also investigated by Chellakili et al. as 
possible antimicrobial compounds. They connected 
two tetrahydropyrimidine rings from their C-4 
positions through a phenyl ring. These compounds 
showed good inhibitory activity against the growth 
of a wide variety of the microorganisms. Compound 
61 shown in Figure 66 is an example of this series 
(128).  
Arylamide derivatives of the 1,2,3,4-
tetrahydropyrimidine-2(1H)-one-5-carboxylic acid 
scaffold were also subjected to antimicrobial 
evaluations. Baldev et al. reported a series of 
compounds with this scaffold and claimed that very 
few of the compounds were less active than 
standard drugs (129) Figure 67. Substitution on the 
arylamide moiety was methyl, methoxy or halide in 
this research. 
Sedaghati et al. prepared carboxylate ester and 
arylcarboxamide derivatives of the THPM ring with 
bulky substitutions containing heteroaromatic 
moieties at C-4 position of the ring. This 
heteroaromatic moiety was a substituted imidazole 
or a simple thienyl or furyl ring. Of note was the 
observation that the antimicrobial THPMs 
investigated in this research were stronger 
antifungals rather antibacterial agents. For example, 
62a and 62b, which are shown in Figure 68, 
inhibited the fungal growth at lower concentrations 
(130). 
 
NH
NHH3C
S
NH
HN
H3C
O
O
S
O
O
                                                           MIC (g/mL)          
                                B. subtilis   K. pneumonia   A. niger     C. albicans
61                                12.5             6.25                   25                  25       
Ciprofloxacin            12.5             12.5                    -                     -
Fluconazole                  -                   -                      12.5               25   
Figure 66. Two 1,2,3,4-tetrahydropyrimidin-2(1H)-thione scaffolds attached through a phenylene linker and the 
corresponding antimicrobial activities 
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H3C O
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O
O
R
  
Figure 67. Arylamide derivatives of 1,2,3,4-THPMs 
possessing antimicrobial activity 
 
 
Maddila et al. provided a series of pyrimidine 
derivatives fused to a thiazolidinone ring. These 
compounds were screened against gram-negative 
bacteria (E. coli and P. aeruginosa), gram-positive 
bacteria (B. subtillis and S. aureus) and fungi (C. 
albicans and A. niger). All the molecules displayed 
moderate to good antibacterial and antifungal 
activity. The halogenated and amino derivatives 
exhibited higher potency (131) Figure 69.  
The same research group reported molecules 
which could be considered acyclic analogues of the 
above compounds. The antibacterial screening data 
revealed that all the tested compounds showed 
moderate to good bacterial inhibition. Compound 
64 exerted ZIs of 25, 20, 29, 23 and 18 mm at 6.5 
µg/mL concentration against E. coli, S. aureus, P. 
aeruginosa, S. pyogenes and K. pneumonia, 
respectively (Figure 70). The corresponding data 
for Ciprofloxacin, used as the standard, were 30, 24, 
33, 25 and 23 mm, respectively, at the same 
concentration,. The prepared compounds were also 
screened for their antifungal activity and proved to 
be moderate to good antifungals against a wide 
variety of fungi.  For instance, 64 emerged as a 
strong compound against A. flavus, A. fumigatus, C. 
albicans, Penicillium marneffei and Trichophyton 
mentagrophytes, with zones of inhibition (in 
millimeters) of 22, 22, 20, 22 and 25 at 6.5 µg/mL, 
respectively (Amphotericin: 21, 25, 19, 25 and 23 at 
the same concentration, respectively) (132).  
Other thiazolo[3,2-a]pyrimidine derivatives 
have been shown to possess significant 
antimicrobial activity. Compound 65a, for example, 
had ZI at 100µg/mL of 16, 14 and 15 (mm) against 
B. cereus, S. aureus and E. coli, respectively. 
Compound 65b demonstrated strong antifungal 
activity against C. albicans (Zone of inhibition at 
100µg/mL = 15 mm). The zones of inhibition at 
100µg/mL for the reference drug, Tetracycline, 
were 21 mm against B. cereus and S. aureus and 22 
against E. coli. Miconazole inhibited C. albicans 
growth with a 19 mm zone of inhibition at 100 
µg/mL (133) Figure 71. 
 
NH
NH
H3C
O
XR
O
                                                                           MIC (g/mL)   
               X             R                E. coli       S. aureus       A. niger       C. albicans
62a        NH     4-ClC6H4           512            >512               64                   3262b         O           C2H5               256            >512             128                   64Ciprofloxacin                             0.25              0.5                -                       -
Ketoconazol                                  -                   -                  4                      2
N
N
S
H3C
NH
  
Figure 68. Chemical structure and antimicrobial activity of 62a and 62b 
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Nagarajaiah et al. reported an antimicrobial 
activity for thiazolo[3,2-a]pyrimidines with no 
substitution on the thiazolo part of the fused ring 
against S. aureus, E. coli and C. albicans that was 
similar to that of Gentamicin and Nystatin (134) 
(Figure 72). 
Akbari et al. explained the antimicrobial 
activity of arylcarboxamide derivatives of 
thiazolo[3,2-a]pyrimidines by the fact that 
pyrimidine analogues (such as compound 67) 
possessed higher antimicrobial activity than 
thiazolopyrimidines (compound 68) due to the free 
C=S group (135) (Figure 73). 
The antibacterial and antifungal activities 
of carbohydrazide derivatives of THPMs were 
investigated in 2012. When they were screened 
against the gram negative bacteria E. coli and P. 
aeruginosa, the gram positive bacteria B. subtilis 
and S. aureus and two fungal organisms, A. niger 
and C. albicans, the molecules revealed weak 
activity against all bacterial strains, while 
compounds 69a and 69b showed good activity 
against A. niger and C. albicans, respectively (136) 
Figure 74. 
N
N
H3C
O
O
S
O
R
                                                                Zone of inhibition at 25 g/mL (mm)         
                     R               E. coli     P. aeruginosa      B. subtilis      S. aureus    C. albicans    A. niger 
63a             p-Cl            13.16          12.15                   13.42             14.60              11.48          12.16
63b       p-N(CH3)2        14.72          11.79                   14.18             13.07              13.44          11.23Streptomycin                12.78          13.36                   12.14             15.39                 -                  -
Amphotericin-B               -                  -                          -                     -                  12.89          14.89
O
O CH3
H3C
  
Figure 69. Antimicrobial activity of pyrimidine derivatives fused to a thiazolidinone ring 
 
NH
N
H3C
O
O
S
64
O
O CH3
H3C
 Figure 70. Chemical structure of 64 
 
N
N
O
OH3C
R
S
O
R1
                R                      R1
65a         p-Cl               p-OCH3
65b        m-NO2              o-Cl  Figure 71. Chemical structures of some thiazolo[3,2-
a]pyrimidines 
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N
N
H3C
O
O
S
                                                 Zone of inhibition at 50 g/disc (mm) 
                         R                     E. coli        C. albicans        S. aureus
66a                 OCH3                  15                15.66                    -66b                  OH                       -                      -                       18 
Gentamicin (10 g/disc)          26                    -                        30  
Nystatin (10 g/disc)                 -                     26  -
R
H3C
  
Figure 72. Antimicrobial activity of thiazolo[3,2-a]pyrimidines 
 
 
 
NH
NH
H3C S
NH
OCl
NH
N
H3C
NH
OCl
S
NO2 NO2
67 68
                                                        Zone of inhibition at 200 g/mL (mm)
                               S. aureus      S. epidermidis      E. coli      P. aeruginosa     C. albicans
67                               22.9                  26                    20                  24.5                   22.5
68                               21.2                  18.5                 17.5               20                      22
Ciprofloxacin           30                      26                    21                 28                         -
Griseofulvin              28                     22                    23                 27                       23   
Figure 73. Antimicrobial activity of arylcarboxamide derivatives of 1,2,3,4-THPMs and thiazolo[3,2-a]pyrimidines 
 
 
NH
NH
H3C X
NH
OHNO
O
HNH3C
O
OH
                                Zone of inhibition at 100 g/mL (mm)
                 X                    A. niger            C. albicans69a           S                        21                         -
69b         NH                       -                         21   
Figure 74. Antifungal activities of carbohydrazide derivatives of 1,2,3,4-THPMs 
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Other hydrazide derivatives have shown a range 
of antimicrobial activities against gram positive and 
gram negative bacteria (Figure 75). Strong electron-
withdrawing atoms (F, Cl) were responsible for the 
good activity of the molecules. Among the 
compounds reported, 70a and 70b were more potent 
than Norfloxacin (137). 
Some more complicated carbohydrazide 
derivatives of THPMs were tested by Alsharifi et 
al. in 2012 for their antimicrobial activity. The 
results indicated that some of these compounds 
exhibit good fungicidal and antibacterial activity 
(138) Figure 76. 
Compounds 72a and 72b shown in Figure 77 
with a heteroaromatic ring at the C-5 position of the 
tetrahydropyrimidine scaffold showed promising 
antibacterial activity against Streptococcus 
pneumonia and E. coli (mean ZI of 15 mm for both) 
compared with standard drugs Ofloxacin (mean 
ZI=19 mm) and Levofloxacin (mean ZI=16 mm). 
The presence of NO2 and OCH3 at para position of 
the C-4 moiety was responsible for providing this 
good antibacterial activity to the molecules (139). 
 
NH
NH
H3C S
O
NH
HN
N
O
R
                          MIC (mol/mL)  
                R       B. subtilis       E. coli   
70a         p-Cl      0.0111         0.0120 
70b         p-F       0.0112         0.0119 
Norfloxacin        0.0124         0.0237   
Figure 75. Chemical structures and antibacterial activities of 70a and 70b 
 
NH
NH
H3C O
NH
O
NS
N
N
O O
                                                    MIC (g/mL)
                            B. subtilis     E. coli      S. aueus     P. picketti
71                          26.24          17.60         20.35           22.25
Tetracyclie           23               14              17.85           18.50
                                                         Zone of inhibition at 1000 ppm (%)
                            T. longifusus      C. albicans    A. flavus     M. canis   F. solani   C. glabrata
71                              88                       72                78                61               79                91
Miconazole               90                      90                 90               90                90               90
Amphotericin           90                      90                 90               90                90               90   
Figure 76. Chemical structure and antimicrobial activities of 71 
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Recently, Elumalai et al. evaluated the 
antimicrobial activities of the acetazolamide 
cyclocondensed 1,2,3,4-tetrahydropyrimidines 
shown in Figure 78. All the compounds displayed 
potent antimicrobial activity. Compounds 
containing p-chlorophenyl or p-fluorophenyl moiety 
at the C-4 position and S or O atoms at the C-2 of 
the dihydropyrimidine ring showed antibacterial 
activity against both gram positive (B. subtilis) and 
gram negative (E. coli) bacteria (140).  
El-Fattah et al. investigated the antimicrobial 
activity of some C-5 unsaturated ketone derivatives 
of the THPM scaffold. These compounds were seen 
to have weak to moderate antimicrobial activity, 
with 74 showing the highest activity against all the 
tested strains, with zones of 7, 10, 10, 9, 12, 11, 8 
and 10 mm at 100 µg/mL against E. coli, S. 
typhimurium, L. monocytogenes, S. aureus, P. 
arginosus, B. cereus, C. albicans and A. flavus, 
respectively. Tobramycin (10 µg/mL), which was 
used as standard antibacterial, showed zones of 
inhibition of 20, 18, 20, 19, 18 and 19 mm against 
E. coli, S. typhimurium, L. monocytogenes, S. 
aureus, P. aeruginosa and B. cereus, respectively. 
Flucanazole (25 µg/mL), which was used as 
standard antifungal, had zones of inhibition=17 and 
16 mm against C. albicans and A. flavus, 
respectively (141) Figure 79. 
An unusual C-5 substitution on the 1,2,3,4-
tetrahydropyrimidine scaffold (Figure 80) led to 
weak antifungal and antibacterial compounds (142). 
 
ANTICANCER ACTIVITY 
 
In the search for novel anticancer drugs 1,2,3,4-
tetrahydropyrimidine derivatives have also been 
considered as promising cytotoxic agents. Among 
these compounds, 76a possessed specific 
cytotoxicity against colon carcinoma cells. 
Compounds 76b and 76c proved to be non-
cytotoxic inhibitors of carcinogen metabolic 
activators (Cyp), inducers of glutathione-S-
transferase (GST) activity, scavengers of ●OH and 
ROO●; and inhibitors of DNA fragmentation. They 
can therefore be regarded as active anti-initiation 
and multi-potent tumor blocking agents (143) 
Figure 81. 
NH
NH
H3C O
NN
O
R
                       R
72a               NO272b                 OCH3   
Figure 77. 1,2,3,4-THPMs with heteroaromatic ring at 
the C-5 position of the scaffold 
 
NH
NH
H3C
NH
O
S
R
                                                       MIC (mol/mL)      
                X              R            B. subtilis             E. coli
73a          O             Cl              0.0129                0.0134 
73b          S              F               0.0114 0.0121 
Norfloxacin                             0.0128                0.0132
O
O
S
N N
HN
H3C
O X
  
Figure 78. Antimicrobial activities of the acetazolamide cyclocondensed 1,2,3,4-THPMs 
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Figure 79. Chemical structure of an 1,2,3,4-THPM 
containing unsaturated ketone moiety at C-5 
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H3C
O
O(H3C)2N
                       Zone of inhibition at 250 g/mL (mm)
                                 S. aureus            E. coli        
75                                  0                        6
Ciprofloxacin              31                      27
OH
O
 
 
Figure 80. Chemical structure and antibacterial activity 
of compound of 75 
 
Chromone derivatives, which also possess 
anticancer activities, were introduced into the 
structure of cytotoxic THPMs, while Raju et 
al.explained the cytotoxicity of a series of 4H-
chromen-1,2,3,4-tetrahydropyrimidine-5-
carboxylate derivatives against three different 
human cancer cell lines (144). Compound 72 shown 
in Figure 82, with a cytotoxicity percentage of 47.6, 
56 and 60.6 against lung (A549), CNS (SK-N_SH) 
and cervical (Hela) cancer cell lines was more 
effective than the standard drug, Doxorubicin 
(cytotoxicity percentage = 55.0, 31.8 and 86.5 
against A549, SK-N_SH and Hela, respectively) 
(145). This compound was the most active amongst 
the studied compound.  
The anticancer activity of a series of THPMs 
against human breast cancer (MCF-7) and colon 
cancer (HCT 116) cell lines was reported in 2012. 
Amongst the studied compounds, molecules 78a 
and 78b were found to be the most effective against 
MCF-7 and HCT-116, respectively (Figure 83). 78a 
had an IC50 of 2.5 µg/mL while the standard drug, 
5-fluorouracil (5-FU) had an IC50 of 0.67 µg/mL 
against MCF-7. 78b, with an IC50 of 5 µg/mL, was 
more potent than   5-FU (IC50 = 6 µg/mL against 
HCT-116). According to a structure-activity 
investigation, the presence of the electron-
withdrawing group on the phenylamino moiety was 
the enhancing factor in the anticancer activity of the 
synthesized compounds against HCT-116. On the 
other hand electron-releasing groups located on the 
phenylamino moiety increased the anticancer 
activity against the MCF-7 cancer cell line. Also, 
the existence of an oxo moiety at the C-2 position 
of the tetrahydropyrimidine ring improved the 
anticancer activity against both tested cell lines, 
although a thioxo moiety did not significantly 
improve the anticancer activity (146). 
Prashantha Kumar et al. reported the in vitro 
anticancer activity of a series of 5-arylcarboxamide 
Biginelli pyrimidines against MCF-7 human breast 
cancer cells. Compounds with a cinnamoyl moiety 
at the C-4 position of the THPM ring (79a and 79b) 
exhibited major activity against MCF-7 cell lines. 
The presence of furan and pyridine moieties at the 
same position provided potential anticancer activity 
to the compounds (79c, 79d and 79e). Based on 3D-
QSAR studies, it was concluded that the 1,2,3,4-
tetrahydropyrimidine scaffold was the basic 
requirement for the cytotoxicity of this class of 
compounds (147) Figure 84. 
THPMs with a substituted pyrazole at C-4 
position were also subjected to in vitro anticancer 
activity evaluation against the MCF-7 cell line. 
Excellent inhibition of MCF-7 growth (70.6% and 
63.7%) at 10 µM concentration was observed for 
80a and 80c, respectively. Structure-activity 
relationship studies revealed that compounds 
containing thioxo moiety at C-2 position were more 
potent than the oxo analogues, which contrasts with 
the observations of Sharma et al. concerning the 
SAR of these compounds (146). The SAR results 
also revealed that the compounds with chlorine (Cl) 
at R1 in the series (80a, 80b and 80c) were more 
potent than compounds with no substitution at this 
position (80d). The structures of the compounds are 
illustrated in Figure 85. 
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Figure 81. Chemical structures of anticancer tetrahydropyrimidine carboxylate esters 
 
 
NH
NH
H3C
O
O
O
O
O
O2N
H3C
77                        Figure 82. 1,2,3,4-THPM containing chromone moiety at C-4 position
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Figure 83. Chemical structures of 78a and 78b 
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NH
NH
H3C
RO
NH
                                                                    
                               R                   X           % Cytotoxicity
79a                     Cinnamoyl        S                     71
79b                     Cinnamoyl        O                    79
79c                      Furan-2-yl        S                     76
79d                     Furan-2-yl        O                     69
79e                     Pyridin-4-yl      S                      72
XCl
 Figure 84. Anticancer activity of some 5-arylcarboxamide Biginelli pyrimidines against MCF-7  
 
 
NH
NH
O
             X         R1                     R2                    GI50 (M)
80a       S         Cl                   OC2H5                      33.2
80b       S         Cl              p-CH3C6H4NH             43.5
80c       O         Cl             p-CH3OC6H4NH           69.7
80d       O         H              p-CH3OC6H4NH            -
H3C X
NN
R1
R2
  
Figure 85. Chemical structures and anticancer activity of 1,2,3,4-THPMs with a substituted pyrazole at C-4 position 
 
 
These results also suggest that replacing the alkyl 
ester moiety (R2) with lipophilic carbamoyl 
influences the GI50 values against MCF-7 breast 
cancer cells (13). 
Desai et al. investigated the correlation between 
anticancer activity against different cancer cell lines 
of several substituted 1,2,3,4-tetrahydropyrimidine 
derivatives and molecular descriptors based on 
quantitative structure-activity relationships. Weak 
correlation was observed between the 
physicochemical parameters and anticancer activity 
against leukemia, lung, and colon cancer cell lines, 
and a very good correlation between the descriptors 
and anticancer activity in the case of a breast cancer 
cell line. The results suggested that less lipophilic, 
less bulky and electron-withdrawing substituents 
may increase the potency against the breast cancer 
cell line. A positive influence of lipophilic and 
electronic parameters and a negative influence of 
steric parameters was observed when descriptors 
were correlated with anticancer activity against a 
prostate cancer cell line. The correlation between 
the activity against the CNS cancer cell line and 
molecular descriptors showed that decreasing the 
lipophilicity and electron density while increasing 
the bulk of the substituent will increase the potency 
(148). 
The cytotoxicity activity of some 5-
arylcarboxamide THPMs against Vero cells has also 
reported (149). Weak to high cytotoxicity was 
claimed for the compounds with the general 
structure of Figure 86:  
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Figure 86. Arylamide derivatives of 1,2,3,4-THPMs 
possessing anticancer activity 
 
 
Tetrahydropyrimidinone derivatives have been 
suggested as human kinesin Eg5 inhibitors. 
Monastrol (ethyl 4-(3-hydroxyphenyl)-6-methyl-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate) 
is known as a low molecular weight, cell-permeable 
molecule, and has inspired a research line for the 
development of potentially new anticancer drugs 
(150) Figure 87. 
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O
Monastrol
H3C S
OH
OH3C
          
Figure 87. Chemical structure of Monastrol 
 
 
This compound specifically affects cell division 
(mitosis) by means of a mechanism that does not 
involve the binding to tubulin, unlike the natural 
Vinca and Taxane alkaloids and Epothilones. It has 
been established that the activity of Monastrol is 
based on the specific and reversible inhibition of the 
motility of mitotic kinesin Eg5, a motor protein 
required for bipolar spindle formation during 
mitosis (151, 152). Investigations showed that 
Monastrol was more potent than its deoxy 
derivative; therefore, the hydroxyl group in the 
aromatic ring is essential for the cytotoxic activity. 
However, the presence of the hydroxyl group seems 
not to be the best option, as can be observed ortho-
methoxy, para-methoxy and meta and para-
methylenedioxy, substituents were all more potent 
than Monastrol (153) Figure 88.  
Soumyanarayanan et al. screened the cytotoxic 
activity of compounds and suggested that 
compounds 81a and 81b (Figure 89) were the most 
potent against the HepG2 cell line, with IC50 = 124 
and 120 μg/mL, respectively. They also introduced 
81a as the most potent compound against the Hela 
cell line (IC50 = 187 μg/mL). Based on the 
biological results, it was anticipated that 
substitution of electron-withdrawing substituents, 
such as chlorine, at the para position of the C-4 
phenyl ring may be essential for the ligand-receptor 
interaction. SAR analysis revealed that compounds 
with weakly basic pyrrolidine and piperidine 
substitutions in the C-5 side chain of these THPMs 
reduce the anticancer activity. In contrast, 
morpholine was not tolerated at this position and 
hence resulted in a decrease in IC50. Modeling the 
molecular interactions of these compounds with 
kinesin Eg5 protein revealed that the positioning of 
a hydrogen bond donor/acceptor on the C-4 phenyl 
ring plays a critical role in the inhibition of this 
enzyme (154). 
 
CONCLUSIONS AND PERSPECTIVES 
 
A detailed study of 1,4-dihydropyridine and 1,2,3,4-
tetrahydropyrimidine scaffolds points to some 
remarkable structural features that mark them as 
potential lead compounds for chemotherapeutic 
applications.  
The nature of the groups substituted at C-3, C-4 
and C-5 positions of 1,4-DHPs proved to be 
important for antitubercular, antimicrobial and 
anticancer activities of the derivatives of this 
scaffold. The structures of the active derivatives 
confirm that the lipophilicity of the molecule is an 
important physicochemical property that affects 
potency. An adequate degree of lipophilicity seems 
to be necessary for the chemotherapeutic properties 
of the compounds. 
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Figure 88. Structures of some anticancer 1,2,3,4-THPM carboxylate esters  
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Figure 89. 1,2,3,4-THPMs with pyrrolidine and 
piperidine substituents in the C-5 side chain 
 
 
The presence of bulk substituents at C-3 and C-
5 positions of 1,4-DHPs, whether aromatic or 
heteroaromatic, increases the chemotherapeutic 
potency. Chain substitution at both positions also 
leads to antimycobacterial and antimicrobial 
compounds that are as potent as heteroaromatic 
substituted 1,4-DHPs. 
Asymmetric 1,4-DHPs bearing both a 
carboxylate ester group and a carboxamide moiety, 
as well as symmetric DHPs with carboxylate ester 
groups in both C-3 and C-5 positions, represent 
potent antitubercular agents. Asymmetric 3,5-
dicarboxamide 1,4-dihydropyridines with two 
different dicarboxamide derivatives were seen to be 
weaker antitubercular agents than symmetric DHPs. 
Both symmetric and asymmetric compounds with at 
least one bulk group were seen to have effective 
cytotoxicity. 
The C-4 substituent has a determinant effect on 
antitubercular, antimicrobial and anticancer 
activities. In almost all the reported 1,4-
dihydropyridines, the C-4 substituent is a 
(substituted) phenyl ring. Substitution on this ring is 
important for the antitubercular, antifungal, 
antibacterial and MDR-inhibiting activities. 
Replacement of the phenyl ring in C-4 position by 
heteroaromatic rings leads to compounds with high 
antitubercular, antimicrobial and anticancer 
activities. The substitution of medium-length (up to 
six carbons) aliphatic chains or cycloaliphatic 
groups at    C-4 may provide key information about 
the SAR of this position.   
N-1 substitution of 3,5-phenylcarboxamide and 
3,5-alkylcarboxylate esters of 1,4-DHPs decreases 
both the antitubercular and antimicrobial potency of 
the compound. 
Aromatic pyridine derivatives have not yet been 
investigated for their antitubercular and 
antibacterial activities. Investigation into the effect 
of aromatization on these biological properties is 
recommended. Aromatized Hanztsch pyridines 
were anticancer agents as potent as 1,4-
dihydropyridines.   
The C-2 and C-6 positions have not been 
subjected to SAR studies. Alterations of the 
substitutents at these positions and exploring the 
effect of the hydrophobic/hydrophilic nature and 
also the steric limitations of these substituents will 
increase our knowledge of the structural 
requirements for chemotherapeutic properties of the 
compound.  
As regards the structural and biological 
similarities between 1,4-dihydropyridines and 
1,2,3,4-tetrahydropyrimidins described above, most 
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of the conclusions provided for the structure-
activity relationship  are applicable to Biginelli 
THPMs. 
Antitubercular, antimicrobial and anticancer 
activities are affected by the properties of the C-2, 
C-4 and C-5 substituents of 1,2,3,4-THPMs. Here 
again, bulk and lipophilic substituents, whether 
aromatic or heteroaromatic, increase the 
chemotherapeutic potency.  
Oxo or thioxo atoms substituted on the C-2 
position of the 1,2,3,4-tetrahydropyrimidine both 
exist in the structure of the active compounds. 
Lipophilic substitutents at this position lead to 
improved antibacterial activity. Such substituents 
should also be investigated for antitubercular and 
anticancer derivatives.    
Evaluation of other lipophilic moieties - 
aliphatic, cycloaliphatic, aromatic or heteroaromatic 
- located at  N-3 and N-1 positions is recommended.  
The importance of the C-4 substituent 
concerning its chemotherapeutic properties is the 
same as that deduced in the case of 1,4-DHPs. 
Again, medium-length (up to six carbons) aliphatic 
chains or cycloaliphatic groups substituted at C-4 
are worthy of further investigation for their 
structure-activity relationships.   
Most of the 1,2,3,4-THPMs studied for their 
potential antitubercular activity bear C-5 
carboxamide moieties, although carboxylate ester 
derivatives proved to be potent antitubercular 
agents. Thus, there seems to be a need for more 
investigation into carboxylate ester derivatives. 
Conversely, carboxamide derivatives need to be 
investigated more for their antimicobial properties. 
Both carboxamide and carboxylate ester derivatives 
have been confirmed as potent anticancer agents.  
Alterations of the substitutents at C-6 position 
will develop the knowledge of structure- 
chemotherapeutic properties relationships 
established for 1,2,3,4-tetrahydropyrimidine 
scaffold.  
The aromatization of Biginelli pyrimidines does 
not seem to add to their antitubercular properties 
and perhaps needs more investigation. The possible 
effect of this structural change on antitubercular and 
anticancer activity of the compounds needs to be 
clarified. 
Determination of exact targets for the 
antitubercular, antimicrobial and anticancer 
properties of 1,4-dihydropyridines and 1,2,3,4-
tetrahydropyrimidines will pave the way for the 
rational structure-based design of novel 
chemotherapeutic derivatives. To the best of our 
knowledge, there are only two reports of modeling 
the molecular interactions of chemotherapeutically 
active 1,4-DHPs. In the first of these, 
Mycobacteriun tuberculosis enoyl reductase as a 
possible target for the antimycobacter 1,4-
dihydropyridine-3,5-dicarboxamides was subjected 
to molecular docking and molecular dynamics 
simulation studies. The second report was a 
molecular docking study of anticancer 1,4-
dihydropyridines in MRP1-NBD1 protein. 
Molecular interactions of 1,2,3,4-
tetrahydropyrimidines were modeled against human 
kinesin Eg5 protein for Monastrol, the FDA 
approved anticancer agent (154).   
Among the ligand-based computer aided drug 
design approaches, the QSAR and 3D-QSAR 
methods provide valuable information about the 
structural features of the biologically active 
molecules (QSAR) and the binding features (3D-
QSAR) of their possible targets. Only a few QSAR 
studies concerning anticancer 1,4-DHPs, 
antimicrobial and anticancer 1,2,3,4-THPMs are 
available in the literature. The same is true for the 
3D-QSAR studies. Antitubercular 1,4-DHPs,  
antitubercular and  antimicrobial 1,2,3,4-THPMs 
have only been submitted to 3D-QSAR 
investigations. The lack of such research is obvious 
in the field of chemotherapeutic 1,4-DHP and 
1,2,3,4-THPM compounds.  
Thus, there is a clear need for computer-aided 
investigations to determine biological target(s) 
among those possibly present in the biochemical 
pathways involved, and for specific laboratory 
assays to experimentally determine such target(s). 
The structural features of the biologically active 
compounds and the binding features of their target 
active sites also need clarification.   
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ABBREVIATIONS 
 
ABC                             ATP-binding cassette 
1,4-DHP                       1,4-dihydropyridine 
3D-QSAR                     3D-quantitative structure–activity relationship 
DXR                            Doxorubicine 
GST                             Glutathione-S-transferase  
MCR                            Multi-component reaction 
MDR                            Multi-drug resistance 
MRP1                          Multidrug resistance protein 1  
Pgp                              P-glycoprotein 
QSAR/QSPKR             Quantitative structure-activity/pharmacokinetics relationship 
RS                               Resistant cells 
SAR                            Structure-activity relationship 
TB                              Tuberculosis 
1,2,3,4-THPM             1,2,3,4-Tetrahydropyrimidine 
TS                              Tumor specific 
VCR                           Vincristine 
VP                              Verapamil 
ZI                                Zone of inhibition 
 
 
 
